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ABSTRACT 
 
  
Feline Upper Respiratory Disease (FURD) is a complex disease characterized by, 
but not limited to, conjunctivitis, rhinitis, and tracheitis. Several pathogens encompass 
this disease including Feline Rhinotracheitis Virus (FHV), Feline Calicivirus (FCV), 
Chlamydophila felis (C. felis), Bordatella bronchiseptica (B. bronchiseptica), and 
Mycoplasma felis (M. felis). This disease process significantly effects cats in group 
housing situations such as animal shelters and is a leading cause of morbidity and 
mortality in these cats. Previous research has investigated the epidemiology of pathogens 
and risk factors in several geographical areas, the development of molecular diagnostic 
tools for the detection of pathogens, and the detection of previously unreported pathogens 
in this complex. This thesis encompasses three papers meant to address the objectives of 
atypical Mycoplasma detection in cats with and without FURD, validation of a field 
deployable molecular device for pathogen detection, and an overall epidemiologic 
evaluation of the unique Midwestern geographical area.  
The first paper investigated the hypothesis that Mycoplasma species occur in the 
cat at higher levels of diversity than previously appreciated utilizing the unique molecular 
based Pan-Myco SYBR qPCR assay for the detection of the Mycoplasma genus and may 
be contributing to FURD. Overall, 15 Mycoplasma species were detected including: M. 
gateae/canadense/arginini cluster, M. canis, M. hyorhinis, M. alkalescens, M. cynos, M. 
faucium, M. dispar, M. buccale, M. spumans, M. hominis, M. bovis, M. bovoculi, M. 
maculosum/leopharyngis cluster, 2 new unknown species, and Acholeplasma laidlawii. 
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Twelve of these Mycoplasma species were previously unreported in cats and several of 
these species are potential zoonotic pathogens.  
The second paper implemented a 5 stage pipeline for development and validation 
of field deployable assays utilizing the Insulated Isothermal Polymerase Chain Reaction 
(iiPCR) on the candidate field deployable device, POCKIT™ for the detection of FURD 
including FHV, FCV, C. felis, M. felis, and B. bronchiseptica. Thirty of both positive and 
negative clinical samples and surrogate samples were randomized, blinded, and tested 
side-by-side on both platforms for each pathogen. Limits of detection were biologically 
relevant, were equal to or less than 10 infectious units, and demonstrated near 
equivalency with clinical samples for all pathogen targets. Exclusivity testing 
demonstrated the iiPCR to be pathogen and target specific. Sensitivity and specificity for 
clinical samples ranged from 80%-97% and 93-100% respectively. Kappa values ranging 
from 0.80- 0.93 demonstrated strong agreement. Results demonstrate exceptional 
performance of the iiPCR reagents for detection of feline respiratory pathogens in clinical 
samples. This study demonstrates the effectiveness of the iiPCR for detection of feline 
pathogens and the use of the stages 1 through 3 of the pipeline for validation of field 
deployable reagents. 
The final paper assessed detection of FURD pathogens in ocular, nasal, and oro-
pharyngeal samples from cats in a specific unique geographical region and evaluated 
their association with disease in a cross-sectional study. There were 71 cats with 
respiratory disease and 119 cats without disease were enrolled in this study. Prevalence of 
FHV, FCV, C. felis, Bordetella species, M. felis, M. gateae cluster, and other 
Mycoplasma species in the total study population was 49%, 19.5%, 3.2%, 23.7%, 40%, 
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24.7%, and 15.3% respectively. Multivariate modeling showed that detection of 
Bordetella species (odds ratio (OR) = 3.143), FCV (OR = 2.830), and housing cats in 
shelters for 2 to 6 months (OR = 0.146) were all significantly related to FURD severity. 
Age of cats and detection of C. felis were confounding factors for relationship between 
Bordetella species and respiratory disease.   
Taken in total, this research illustrates the necessity for continued research in the 
field of FURD. The discovery of previously unreported pathogens in felines, the 
application of new and emerging detection platforms for triage of disease outbreak, and 
the continued exploration of pathogen association and risk factors all contribute to the 
management of this disease in shelters. The impacts and translation of this research will 
help to prevent the high morbidity and mortality in shelter cat populations.
1 
 
 
CHAPTER 1: GENERAL INTRODUCTION 
This thesis focuses on the microbiological epidemiology of the feline respiratory 
tract in both healthy and diseased states in Midwestern shelter cats. Studies of Feline 
Upper Respiratory Disease in cats are performed to better understand the disease 
complex, predisposing factors, pathogens involved, and methods to detect those 
pathogens in an effort to better control respiratory disease in shelter populations.  
Background 
According to a survey of American pet owners in 2013, 68% of U.S. households 
owned a pet and 45.3 million of those households owned cats[1]. The total number of 
cats owned in the US was reported to be 95.6 million[1]. In 2012 it was reported that 
there were 6 to 8 million cats and dogs entering shelters across the U.S. each year with 
only 3 to 4 million being adopted from those shelters[2]. Additionally while 30% of lost 
dogs are reclaimed from shelters by their owners, only 2-5% of lost cats are reclaimed[2]. 
These numbers suggest that in the U.S. cats entering shelters have a high rate of 
mortality.  
In 2006, a large needs-based assessment was performed in the western United 
States. The survey involved animal shelters in six states including responses from 78 
shelters, which represented over 150,000 animals. This study reported that one of the 
three diseases of most concern for shelters and their feline populations was Feline Upper 
Respiratory Disease (FURD)[3]. FURD is a disease complex, similar to other respiratory 
disease complexes in domestic animal species, caused and compounded by the presence 
of several pathogens with many different predisposing and risk factors for disease.  
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While many of the risk factors for disease such as stress, high population density, 
and mixed age groups are rarely issues faced by household owned cats, cats entering 
animal shelters face all of these risk factors. These risk factors and others in combination 
with exposure to pathogens make animal shelters prime locations for respiratory disease 
outbreaks. All too often respiratory disease is endemic within a shelters feline population. 
For this reason, FURD is generally considered to be the leading cause of feline death in 
shelters and a leading cause of death in young cats overall[4].  
Goals and Objectives 
 The overall goal of this collection of research was to improve the health and 
wellbeing of cats in shelter environments through increases in the general knowledge of 
FURD. This included education regarding the risk factors, associated pathogens, and 
translational application of pathogen detection assays for feline infectious agents. This 
goal was achieved through three specific objectives: 
1) Translation and application of a broad pathogen detection assay to assess for 
the presence of previously unreported Mycoplasma pathogens in the feline 
upper respiratory tract and their association with respiratory disease,  
2) To implementation of a 5 stage validation pipeline for the development of 
field deployable diagnostics using FURD pathogens proof of concept with an 
point of need assays and a platform which could be implemented in a shelter 
environment, and  
3) Determination of the specific risk factors and pathogens contributing to FURD 
in Midwest shelters. 
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Thesis Organization 
 This research based thesis will encompass three complete manuscripts and follow 
the journal paper format. Chapter 1 provides a brief introduction to the feline 
overpopulation problem in the United States and subsequently the importance of FURD 
research for domestic cats in shelter environments.  This introduction provides both the 
rationale for the following studies and also the goals and objectives of the overarching 
research plan. Chapter 2 provides a literature review which includes a brief overview of 
the main pathogens associated with FURD, the evidence regarding risk factors associated 
with FURD, and finally a review of the current body of literature on the prevalence of 
FURD and associated pathogens in shelter cats.  
Chapter 3 is a manuscript titled ‘Identification of Diverse and Unique 
Mycoplasma Species in the Feline Upper Respiratory Tract Utilizing the Pan-Myco 
SYBR Real-Time PCR Assay’ for submission to Plos Pathogens. Chapter 4 is a 
manuscript titled ‘Validation of a portable molecular diagnostic device for detection of 
pathogens associated with feline upper respiratory disease in cats’ for submission to The 
Journal of Veterinary Diagnostic Investigations. Chapter 5 is a manuscript titled ‘Feline 
Upper Respiratory Disease Pathogens in Midwestern Shelter Animals: a cross-sectional 
study’ for submission to Preventive Veterinary Medicine. Chapter 6 is then comprised of 
general conclusions from this body of research. As this paper follows the journal paper 
format, references included in a chapter will be located at the end of that chapter and will 
either follow the formatting guidelines for the intended journal of submission or that of 
Plos for those chapters with general content.  
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CHAPTER 2: LITERATURE REVIEW 
Feline Upper Respiratory Disease Pathogens 
 Feline Upper Respiratory Disease is a complex which has many contributing 
pathogens. These pathogens serve as both primary and secondary invaders and work in 
conjunction to produce the severity and diversity of clinical signs.  
Feline Herpesvirus-1 
 Feline Herpesvirus-1 (FHV) accounts for around half of the viral feline upper 
respiratory infections which are diagnosed [1]. FHV is a member of the 
Alphaherpesviridae subfamily which encompasses a majority of the human and animal 
herpesviruses. FHV is an enveloped double stranded DNA virus which only replicates in 
feline cells, including both domestic and wild cats [1,2]. One characteristic of 
alphaherpesviruses, shared by FHV, is viral persistence in a latent state in nervous and 
lymphoid tissues [1]. The virus is considered to be endemic in the domestic cat 
population with over 90% of cats being found serologically positive and the majority 
remaining latent throughout life [3]. FHV is not a hardy virus and does not survive for 
long periods in the environment. It is also susceptible to a large number of disinfectants 
including quaternary ammonia compounds [4]. FHV is spread through direct contact, 
fomites, and aerosolized droplets created through sneezing which can travel up to 1.3 
meters [5].  
Maternal immunity to FHV is lost around 2 months of age. After that time, FHV 
can induce acute severe upper respiratory tract disease characterized as feline viral 
rhinotracheitis. It has been experimentally shown that installation of 10
2
 to 10
7
 CCID50 of 
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FHV in the nostrils will reliably reproduce disease [6]. After oro-nasal inoculation with 
FHV, the virus incubates for 2-6 days [1],  replicating in the upper respiratory mucosa 
causing clinical signs. Infected cats will begin to shed virus after 24 hours and continue 
for 1 to 3 weeks [7]. Clinical signs include pyrexia, anorexia, sneezing, and serous nasal 
discharge for 10 to 14 days [4]. FHV has cytolytic properties which can result in oral 
mucosal ulceration as well as dendritic ulcers in the cornea, considered pathognomonic 
for this virus [1]. Conjunctival hyperemia, serous ocular discharge, and chemosis can also 
be present [1,7]. In cats, a reoccurrence of active infection can be induced by stress, 
including rehoming, or administration of corticosteroids [8,9].   
 Treatment for FHV infection in cats is mainly focused on supportive care and 
prevention of secondary bacterial infections. Antiviral therapy is most effective in cats 
when supplied topically using Idoxuridine, a drug which is well tolerated by cats and has 
high clinical efficiency [5]. Oral supplementation with L-Lysine has also been shown to 
reduce the severity of disease both during initial infection and after recurrence from 
latency [10,11]. FHV is considered to be a component of core vaccination schedules for 
cats and is included in several combination vaccine products called “FVRCP”s [1]. The 
American Association of Feline Practitioners recommends the use of modified live 
vaccination on a schedule of a single dose at intake to a shelter environment and 
depending on the age of the cat, either one booster 2 to 3 later or every 2 to 3 weeks until 
16 weeks of age [12]. Other preventative measures include isolation of all cats at intake, 
isolation of all cats with clinical symptoms, and prevention of aerosol transmission 
through barriers between cats [7]. 
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Feline Calicivirus 
Feline Calicivirus (FCV) is a highly variable single-stranded RNA virus in the 
family Caliciviridae and the genus Vesivirus. FCV infects both domestic and wild cats 
and has not been reported to be zoonotic or pathogenic to other domestic animal species 
[2,13]. The capsid protein is the most variable region of the virus, the target for the 
immune system, and allows for wide viral variability [17]. FCV has been proven to cause 
respiratory disease in cats through experimental infection [14-16]. FCV causes a variety 
of clinical signs and syndromes with the variability in strains leading to a large spectrum 
of disease severity and clinical manifestations [17]. It is the second important viral cause 
of FURD as well as chronic stomatitis, lingual ulceration, and transient limping [17-19].  
FCV is widespread in feline populations of cats with and without clinical 
symptoms. Maternal antibody persists for up to 14 weeks but kittens become susceptible 
to FCV infection earlier [20]. FCV is transmitted through the respiratory mucosa (oral, 
nasal, and conjunctival) and replicates in the oropharynx [21]. Experimental infection 
demonstrated that an infectious dose of 10
4
 TCID50 caused serous nasal and ocular 
discharge, minimal sneezing, and lingual ulcers [16] Once in the host, FCV becomes 
viremic, often with associated pyrexia, and the virus causes necrosis of epithelial cells 
resulting in clinical signs such as oral ulceration [21]. Depending on the strain oral and 
respiratory signs may give way to limping and acute arthritis [22,23]. FCV also has a 
more virulent systemic variant which causes vasculitis, edema, and jaundice. In severe 
cases FCV can cause hemorrhage with mortality rates as high as 40% [24-26].  This 
variant is more severe in adult cats. After a cat recovers from acute infection, the virus 
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can be shed by that cat for up to 30 days or longer and may represent a persistent carrier 
state [21,27].  
Due to the severity of disease that FCV can cause, infected cats with clinical signs 
may require intensive nursing and supportive care. With cats, especially with diseases 
that cause oral pain, it is very important to provide nutrition, via palatable feed or 
placement of feeding tubes, to prevent the development of hepatic lipidosis [21]. Non-
steroidal anti-inflammatories can also be used to address the pyrexia and oral pain 
involved in infection [21]. Because FCV is a RNA virus, current antiviral therapies have 
limited efficacy. Feline interferon-omega, used for treatment of Feline Leukemia Virus, 
has been demonstrated to be efficacious against FCV. Feline interferon-omega inhibits 
FCV viral replication in-vitro and improved both pain and oral lesions in cats [28,29]. 
FCV is considered to be a core vaccine component for cats [12]. FCV is commonly a 
component of the “FVRCP” vaccine and the recommended vaccination protocol is the 
same as previously discussed for FHV.  If disease occurs in a fully vaccinated cat a 
different vaccine should be used as infection may have occurred with a different strain of 
the virus [12].  
FCV can persist in the environment for up to a month and is shed for long periods 
of time [21]. Early disease detection, isolation, and proper disinfection are essential in 
shelter environments to limit the spread of disease. FCV has been shown to be 
susceptible to sodium hypochlorite, chlorine dioxide, and potassium peroxymonosulfate 
disinfectants, but not to quaternary compounds [4]. Thus it is important to make sure that 
a shelter is utilizing chemicals that will remove the virus from the environment 
effectively.   
9 
 
 
Chlamydophila felis 
Chlamydophila felis (C. felis) is an obligate intracellular gram negative bacteria 
which has a unique infectious cycle involving reticulate and elementary bodies which are 
released upon cell lysis, with the elementary bodies being infectious [30]. Chlamydia 
species share close homology and C. felis has been reported to have zoonotic 
transmission to humans from cats [31-34]. C. felis antibodies have also been reported in 
civets and bearcats [35].  C. felis has been proven to cause upper respiratory disease and 
conjunctivitis in cats through experimental infection [36-38]. One study determined that 
an infectious dose of 10
2.8
 CEID50 reproducibly causes both unilateral and bilateral 
conjunctivitis [38].  
Most C. felis infections occur in cats less than 1 year of age and C. felis is spread 
through direct or close contact between cats and ocular fluids [30]. Maternal antibody 
protects kittens from 1 to 2 months of age [30]. Once on host mucosal tissues, C. felis 
requires 2-5 days for incubation after which point acute unilateral conjunctival chemosis 
and hyperemia can be seen [30]. Unilateral disease normally progresses to bilateral 
disease and serous to mucoid ocular discharge, blepharospasm, and discomfort are 
characteristic [30]. Transient pyrexia, anorexia, and lethargy can also accompany 
infection.  Conjuctival shedding of the organism can exceeded 60 days [38].  
 Several studies have shown that C. felis is effectively treated through systemic use 
of Doxycycline at a 10 mg/kg/day dose [39-41]. Potentiated Amoxicillin is safe treatment 
with few side effects and may be best for young kittens  [30] but Doxycycline therapy for 
at least 28 days is preferred [41]. Cats treated with potentiated Amoxicillin may have 
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recurrence of clinical signs and require additional therapy [40].  C. felis is not considered 
a core-vaccine in cats but instead a vaccine given once pathogens have been isolated in 
the population and risk assessment suggests it will be helpful for disease control [12]. 
One study utilizing a live C. felis vaccine demonstrated that vaccination decreased 
clinical signs but did not affect the shedding of infectious particles [42]. Vaccination 
schedules for C. felis begin between 8 to 12 weeks of age and require a booster 3 to 4 
weeks later with a yearly booster for cats with exposure [30]. C. felis detection in cats in 
shelter environments is not as common as the viral causes of FURD [43].  This bacteria is 
not thrifty in the environment and routine hygiene utilizing quaternary ammonia dilutions 
is sufficient [32].  
Bordetella bronchiseptica 
 Bordetella bronchiseptica (B. bronchiseptica) is a gram negative coccobacillus 
with a wide animal host range including cats, dogs, swine, and rabbits [44]. Additionally, 
B. bronchiseptica has been implicated in several zoonotic transmissions from cats to 
humans and specifically a concern for immune-compromised pet owners [45-47]. 
Transmission has also been reported between domestic animal species and passage has 
been documentation from a dog to a cat [48]. These transmissions are especially 
important when considering shelter housing where cats and dogs may be exposed to one 
another and shelter personnel are exposed to both species [49]. Experimental infection of 
cats via aerosol methods and intranasal injection with 10
7.5
 colony forming units (CFU) 
has reliably produced disease [50-52].  
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 B. bronchiseptica is shed in the nasal and oral secretions of cats and spread 
through direct and indirect contact [53]. Maternal antibody against B. bronchiseptica is 
low in kittens and may only last for 2 to 8 weeks post-partum [50,52]. Clinical signs 
cause by infection range from mild pyrexia, coughing, sneezing, and ocular discharge to 
more severe disease such as pneumonia, cyanosis, and dyspnea [44,50,52,53]. Disease 
may be more severe in kittens under 10 weeks of age [44].  One of the distinguishing 
features of B. bronchiseptica infection is it is one of only a few infectious causes of feline 
cough. Clinical signs average 10 days with bacterial isolation possible up to 10 weeks 
post infection, suggesting that animals may be shedding bacteria long after the resolution 
of clinical signs[44].  
 Antimicrobial therapy is important in the case of B. bronchiseptica infection to 
prevent the extension of upper respiratory disease into the lower respiratory tract 
resulting in pneumonia [44]. When possible, bacterial culture and sensitivity should be 
performed to assess for appropriate antimicrobial as several studies have shown that 
Bordetella species have varying resistance. Tetracycline drugs appear to have the lowest 
percentage of resistance (1.3-2%), while resistance to potentiated Amoxicillin was much 
higher (14.5%) [54,55]. A study of disinfectants utilized for swine facilities suggests that 
B. bronchiseptica is highly susceptible to most common disinfectants as long as organic 
material is removed first [56]. Bordetella vaccination is not considered a core-vaccine for 
cats and vaccine recommendations for shelters are the same as those for C. felis [12]. 
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Mycoplasma felis 
 Mycoplasma felis (M. felis) is a prokaryotic organism from the class Mollicutes 
which lacks a cell wall and survives on mucosal surfaces where it acts as both primary 
and commensal opportunistic pathogen [57]. M. felis infects both domestic and wild cats 
as well as horses [58,59]. Zoonotic transmission from cats to humans has also been 
reported through a cat bite and increased feline exposure [60,61]. Experimental infection 
of kittens with 10
7
 CFU in both the nostrils and conjunctiva reliably produced disease 
[62,63].  
 Infection with Mycoplasma can occur through respiratory aerosols and 
reproductive secretions from infected animals. In group housing Mycoplasma can also be 
transmitted through fomites and close contact [64]. Once infected, M. felis can cause 
conjunctivitis, ocular and nasal discharge and anorexia [62,65]. M. felis can also cause 
chronic rhinosinusitis [66], ulcerative keratitis [67], and can progress into pneumonia and 
arthritis [68,69]. Treatment of Mycoplasma infection is effectively performed using 
Pradofloxacin or Doxycycline[70]. One study showed that an extended 14 day treatment 
regimen of Doxycycline was most effective for reduction of DNA detection [71].  
 Several species of Mycoplasma have been reported as being able to form biofilms 
and have also been shown to survive for extended periods when dried onto surfaces [72]. 
Thus they can become environmental contaminants and persist on fomites. Quaternary 
ammonium compounds have not been shown to be effective against Mycoplasma species 
but 70% Ethanol and alkaline cleaners  as well as bleach products have been effective for 
killing Mycoplasma with a 5 minute contact time[73].  There is currently no vaccine 
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available for M. felis and measures such as regular disinfection, isolation of sick animals, 
and reduction of respiratory aerosols are the mainstays of infection prevention.  
Evidence for Predisposing Factors 
 Many studies of FURD pathogens also included data on predisposing risk factors 
and protective factors that influence the development, progression, and maintenance of 
disease.  
Age 
Several studies have reported that younger animals are at greater risk for 
developing FURD [43,74-76]. This may be due to the waning of maternal antibody, the 
stresses of weaning, and the lack of vaccination histories of both the queen and the 
kittens. The risk is also significantly increased for cats greater than 11 years of age [75]. 
Older animals may have additional health concerns which increase their stress levels as 
well as impair their immune systems. Additionally, animals surrendered to shelters at an 
older age may have greater stress induced by rehoming. The results in these studies are 
influenced by the ages that sampling included and the ability to determine age of cats 
based on records or dental analysis. Determining the age of cats with dental records after 
two years of age is fairly subjective. This is because all teeth have erupted at this point 
and the scale utilized by most shelters requires evaluation of dental plaque and color 
[77,78].  
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Sex and sterilization status 
While several studies agree that there is no sex predisposition to FURD 
[43,79,80], Studies disagree on the influence of spay/neuter surgery. One study found 
intact cats to have a higher incidence of disease[74] , another finding neutered males at 
higher incidence [81], and another finding the incidence of FURD to be lower in spayed 
female cats as compared to male cats [75]. These findings can be complicated by the fact 
that younger animals coming into shelters tend to be intact and older animals coming into 
shelter populations are more likely castrated [81]. Additionally, the reporting of 
reproductive status cannot always be determined in female cats unless an obvious spay 
incision is visible or palpable. With the recent trend of pediatric spaying, identification of 
spayed females is more difficult and implementation of tattooing post-surgery is 
essential.  
Source 
 Sources evaluated previously generally include either stray animals or owner 
surrender animals. Stray cats are generally found to have a higher incidence and risk of 
developing FURD than owner surrender cats in the same populations [75,81,82]. One 
study reported a 17% increase in risk for stray cats [81]. Owner surrendered cats are more 
likely to have a vaccine history and have received preventative medicine and less likely 
to have concurrent immune-suppressive diseases such as Feline Immunodeficiency Virus 
(FIV) and Feline Leukemia Virus (FeLV) on presentation to shelters which may 
contribute to this difference in incidence of disease. Conversely, owner surrender cats are 
likely to be middle aged to older cats accustomed to one housing situation and more 
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susceptible to higher stress in the shelter environment. More research is needed to 
determine the different contributing factors for these two cat populations and their 
individual risks.  
Breed 
 Although it may be difficult to determine a cats breed on entry to the shelter, one 
study found that purebred cats were at a higher risk of developing FURD than mix breed 
cats [75]. This result may have been skewed by the small number of purebred cats 
included in the study and the fact that 1/3 of the purebred cats were kittens. Another 
study found the highest detection of FHV and FCV in domestic shorthair cats [74] while 
a second study found purebred cats to be significantly at risk for development of FURD 
[76]. These conflicting results are likely due to the number and definition of purebred 
cats included in the study populations. 
Vaccination history 
While many studies record whether cats were vaccinated upon arrival to the 
shelter and whether cats had vaccine histories on intake, only one study remarked on 
whether this was significant. This study reported that FURD was more common in 
unvaccinated cats [74].  
Time in shelter 
 Several studies agree that the longer the time spent in the shelter the higher the 
risk of FURD [43,75]. Studies have shown that being housed in the shelter longer than 6 
days increased FURD risk [43] and that FURD incidence remains low until day 6 and 
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between day 6 and 13 it rises to almost 80% incidence [75]. Conversely, it has also been 
shown that the risk of FURD decreases over time spent in the shelter [76]. The study 
suggests that early exposure and disease occur within the first 6 to 12 days in the shelter 
followed by latency and remission of disease [76]. In this study, the majority of FURD 
infections occurred within the first 50 days in the shelter [76]. The study of ‘time in 
shelter’ is complicated by the fact that most shelters, unless they are no-kill, do not hold 
cats for extended periods of time. In addition, population turnover is high and dictated by 
adoption, foster, and euthanasia.  
Hygiene 
 Two studies demonstrated that a decrease in hygiene of the feline environment 
was associated with an increase in FHV, FCV, C. felis, and B. bronchiseptica [49,83].  As 
several of these pathogens have been shown to be stable in the environment in respiratory 
exudates and on fomites, an environment without proper cleaning protocols would lead to 
a buildup of pathogens and an increase in the infectious dose to which animals are 
exposed.  
Presence of dogs 
Cats housed in close proximity to dogs have also been shown to be at increased 
risk of developing FURD [49,83]. As transmission between canines and felines of B. 
bronchiseptica has been demonstrated previously, the spread of these bacteria between 
closely housed cats and dogs may be the cause of this relationship. Additionally, cats 
rehomed in shelters that had previously never been housed with dogs may experience an 
increase in stress level when exposed to dogs and canine related noise.  
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Season 
One study found that the peak incidence for reported disease caused by FHV and 
FCV was during the winter months[74]. This effect can be explained by the stability of 
both viruses at lower temperatures, the stress winter time may put on cats, and the fact 
that owners may spend more time indoors and notice milder clinical signs [74,84].  
Review of the Prevalence of FURD and FURD Associated Pathogens in Shelter Cats 
 Several studies have been done around the world assessing both the prevalence of 
FURD and associated pathogens. The objective of this section of the literature review is 
to conduct a critical comparative review of the current literature of prevalence estimates 
for both FURD and the detection of associated pathogens in the shelter environment.  
Review of prevalence studies in literature: 
 Literature review was conducted in two portions. First review was performed for 
Feline Upper Respiratory Disease (FURD). The case definition used for FURD was for 
reporting of prevalence estimates in shelter animals displaying clinical signs of upper 
respiratory disease. The target population was specifically cats housed in shelter 
environments and the definition of FURD addressed displays of clinical signs including 
sneezing, ocular discharge, nasal discharge, and oral lesions.  
The second review was for the individual pathogens which can be etiologic agents 
of FURD including FHV, FCV, C. felis, B. bronchiseptica, and Mycoplasma species. For 
each of the pathogens, the target condition was the prevalence of detection of the 
pathogen in feline upper respiratory samples (i.e. ocular, nasal, or oro-pharyngeal 
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samples). Due to the many different diagnostic tests available per pathogen, isolation 
and/or detection was the target condition and substantial replication or histopathology 
was not necessary as several of these pathogens have had reported latent phases and the 
widest target definition was utilized.  
A review of prevalence studies for both topics was conducted on February 26, 
2014. Studies from 1990 to the present were included in the search parameters. Search 
occurred on the web based databases Web of Knowledge, PubMed, and Google Scholar. 
The search terms were: Feline/cat Upper Respiratory Disease combined with shelter. 
Additional searches were performed for individual pathogens using the search terms 
individual pathogen name, feline/cat, shelter, and respiratory. When searching for the 
pathogen C. felis the search term conjunctivitis was also included.  
Data extraction and quality assessment 
 Data extraction was performed in several steps. First all articles which were 
reviews of disease and not specifically novel reporting from shelters were eliminated. 
Additionally any reports that were clinical trials of antimicrobials, vaccines, or other 
therapies were also excluded. Publications not reporting prevalence and publications 
reporting a single animal case study or lethal outbreak situation were excluded. Studies 
prior to 1990 were excluded and data from cat populations other than shelter animals 
were excluded.  
 The following data was collected from the remaining publications: country and 
region, year of study, FURD or specific pathogen prevalence reported (some articles 
reported both and were included in both analysis), test utilized for detection/isolation of 
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pathogens/determination of clinical status, study population size and age distribution, 
anatomical sampling location, and for pathogen prevalence what was the clinical FURD 
condition of the cats included. The majority of studies failed to report or vaguely reported 
much of the information sought and the overall quality of the studies was poor. One study 
was removed due to an inability to determine the prevalence reported for the agents [85] 
and two others were removed because the shelter populations studied could not be 
distinguished from other non-shelter populations of cats in the studies[83,86].  
 The majority of papers had critical issues regarding collection of relevant 
information. Highest among these was the lack of reporting of test accuracy, or 
sensitivity and specificity. Because different papers utilize different testing platforms 
with different accuracy levels, knowing the sensitivity and specificity of the testing 
performed allows for the calculation of true prevalence (TP) from the reported prevalence 
(RP). TPs then allow for the comparison of prevalence findings across reports and assay 
types. Additionally, for many of the studies, the selection of cats included in the study 
populations was not random which resulted in selection bias. For the included studies, 
reported critical issues were also noted and placed into one of several categories which 
were: (a) no study definition of FURD was reported; (b) study had unclear explanation of 
inclusion criteria for cats and therefore selection bias could not be determined; (c) disease 
status was determined by more than one observer with no reporting of measures of inter-
observer agreement; (d) study was either designed for non-random sampling or reported 
that non-random sampling occurred; (e) no definition was provided for what constitutes a 
positive detection of target pathogen; (f) no sensitivity or specificity information 
provided for assay. These critical issues are reported along with other data collected as 
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indicated by the letter assigned the category. Critical issues with the reported studies were 
taken into consideration when determining whether a prevalence estimate from a study 
could be compared to other studies.  
Data Analysis 
 The AP reported was either determined through reporting of the individual study 
or was calculated as the number of animals positive for a target out of the total number of 
animals tested for the target. The definition of test positive was determined by the 
individual studies and frequently what constituted a positive was not reported (i.e. what 
was the PCR cut-off for positive values, etc). Tests used to determine FURD status in 
studies were all subjective and based on clinical exam findings [75,76,79,81] and while 
every study utilized similar clinical symptoms, no validation study was performed on the 
scoring systems. TPs were calculated using the Rogan-Giaden estimating formula as 
reported in a previous study[87]. Microsoft Excel ™ was utilized to perform the formula:                               
TP = (AP + Sp -1) / (Sp + Se – 1). 
For assays which had no sensitivity or specificity reported, sensitivity and 
specificity sensitivity and specificity for the same platform and a highly related target 
were utilized. For example, as no sensitivity and specificities were able to be determined 
for FHV for viral isolation, viral neutralization, and PCR, assay sensitivity and 
specificities as determined for Herpes Simplex Virus (HSV), another alphaherpesvirus, 
were utilized instead [88]. The sensitivity and specificity for testing for C. felis was 
performed using those determined for Chlamydophila species in cattle [89]. B. pertussis 
assay measures were substituted for B. bronchiseptica measures as they are closely 
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related Bordetella species[90]. All included M. felis reports utilized polymerase chain 
reaction (PCR) platforms and as such no TP was calculated. No sensitivity and specificity 
data could be found for FCV assays and as the FCV virus is highly variable no surrogate 
target was used and no TPs were calculated.  
Results 
Literature search 
 Initial searches performed resulted in 5449 hits (5390 on Google scholar, 37 on 
Web of Knowledge, and 22 on PubMed). After exclusion of repeat records, records that 
did not include shelter populations, records which were vaccine or antibiotic trials, and 
records which were conference proceedings 16 publications remained. Of these 2 were 
excluded because the shelter population could not be separated from the general study 
population and 1 was excluded because prevalence could not be determined from the 
reported results.  
 The remaining 13 publications were included in this prevalence study. The 
publications compromise studies from across the United States, Canada, the United 
Kingdom, Germany, Belgium, and Korea. Of these studies, 4 reported on overall FURD 
prevalence in a shelter and 1 of these papers also reported individual target prevalence 
[81]. There were 8 studies which reported FHV prevalence, 8 reporting FCV prevalence, 
5 reporting C. felis prevalence, 6 reporting B. bronchiseptica prevalence, and 4 reporting 
Mycoplasma species prevalence.  
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FURD in shelters 
 A summary of the 4 shelters reporting overall FURD prevalence in shelters is 
presented in Table1.1. This table includes information on the location and time period of 
the study, the clinical definition of FURD used by the study, the reported prevalence of 
FURD, the study size, the distribution of feline age in the study, and the reference. As the 
reported prevalence in each of these studies was based on subjective clinical scoring of 
disease in the cats, no TP was calculated.  
Table 1.1. Summary of the prevalence of Feline Upper Respiratory Disease in shelter cat 
populations in studies published from January 1990 to February 2014.  
Country/ 
Region 
Study 
period 
Clinical 
definition  
RP (%) n 
Age 
distribution 
CI
1
 Reference 
Canada/ 
Vancouver 
2010 Undefined 33.60 250 6 mo -8 yr a,b 
Gourkow et 
al, 2013 
USA/ 
Northeast 
2009- 2010 
Listed 
signs 
30.00 
2734 
 
kittens and 
older 
c 
Dinnage et 
al, 2009 
UK 
 
2002- 2003 
Scoring 
system  
4.10 1434 3-72 mo c,d 
Edwards et 
al, 2008 
UK 1994 - 1995 
Scoring 
system  
36.80 185 
1 mo –  
7+ yr 
c,d 
Binns et al, 
2000 
Abbreviations: RP, Reported Prevalence; n, number of cats tested; CI, Critical Issues. 
1
Critical issues: (a) no study definition of FURD was reported; (b) study had unclear 
explanation of inclusion criteria for cats and therefore selection bias could not be 
determined; (c) disease status was determined by more than one observer with no 
reporting of measures of inter-observer agreement; (d) study was either designed for non-
random sampling or reported that non-random sampling occurred.  
 
Pathogens in shelters 
 Table 1.2. presents a summary of the 8 prevalence studies on FHV in shelter 
environments. Table 1.3. presents a summary of the 8 prevalence studies of FCV. Table 
1.4. presents a summary of the 5 prevalence studies of C. felis. Table 1.5. presents a 
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summary of the 6 prevalence studies of B. bronchiseptica. Table 1.6. presents a summary 
of the 4 prevalence studies of Mycoplasma species. Each table includes a summary of the 
location and time period of the study, the anatomical sampling location, the testing 
platform and detection target, the reported prevalence, sensitivity and specificity of the 
testing platform (with the exception of FCV and Mycoplasma species), the calculated true 
prevalence (when performed), the total study size, age of distribution, what percentage of 
the pathogen positive animals had FURD, and any critical issues present in the study.  
Critical review of the prevalence of FURD 
 All of the studies which reported a prevalence of FURD were given critical 
comments, as reported in Table 1.1. One study did not provide a definition for the 
outcome FURD and only reported that it was determined [81]. This study also did not 
clearly state the criteria for inclusion of a cat in the study and it was therefore impossible 
to determine if selection bias had been introduced in the study [81]. Three studies were 
designed in such a way that multiple observers recorded disease scores for the cats in the 
studies. None of these studies remarked on inter-observer agreement and the possible 
reporting bias created by using multiple observers [75,76,79]. One paper did comment on 
specific training that all observers received [76]. One study reported that, while the 
design of the study involved sampling all animals taken into a shelter, this practice was 
not implemented and selection 
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Table 1.2. Summary of the prevalence of Feline Herpes Virus in shelter cat populations in studies published from January 1990 to 
February 2014. 
Country/ 
Region 
Sampling site Test Target 
RP 
(%) 
Se Sp TP n 
Age 
distribution 
%  with 
FURD 
CI
1
 Reference 
Canada/ 
Vancouver 
Conjunctival/ 
oral-nasal 
PCR 
Glycoprotein 
B 
2 1 0.78 2.28 250 6 mo -8 yr 100 a,e,f 
Gourkow et al, 
2013 
USA/ 
Florida 
Blood VN Antibody 11 0.81 0.99 13.79 347 >6mo – 5+yr NR f 
DiGangi et al, 
2012 
USA/ 
California 
Conjunctival/ 
Deep laryngeal 
PCR 
Glycoprotein 
B 
78.2 1 0.78 99.7 101 NR 89.9 a 
Burns et al, 
2011 
Germany Conjunctival PCR Not reported 25 1 0.78 31.68 20 3 mo - 16 yr 100 d,e,f 
Hartmann et 
al, 2010 
Belgium/ 
Liege 
Oral PCR 
Glycoprotein 
gC 
30.1 1 0.78 38.2 299 2-180 mo NR e,f 
Zicola et al, 
2009 
Korea/ 
Yangju 
Conjunctival/ 
oro-pharynx 
PCR TK gene 63 1 0.78 80.26 78 NR 0 d,e,f 
Kang, et al 
2008 
USA/ 
California 
Conjunctival/ 
oropharyngeal 
VI CPE 23.4 0.81 1 28.92 573 0-96+ mo 70 e,f 
Bannasch et al, 
2004 
USA/ 
California 
Oropharyngeal VI CPE 0 0.81 1 0 42 NR NR f 
Foley et al, 
2002 
Abbreviations: PCR, Polymerase Chain Reaction; VN, Viral Neutralization; VI, Virus Isolation; CPE, Cytopathic Evidence; RP, 
Reported Prevalence; Se, Sensitivity; Sp, Specificity; TP, True Prevalence; n, number of cats tested; CI, Critical Issues; NR, Not 
Reported.  
1
Critical issues: (a) no study definition of FURD was reported; (b) study had unclear explanation of inclusion criteria for cats and 
therefore selection bias could not be determined; (c) disease status was determined by more than one observer with no reporting of 
measures of inter-observer agreement; (d) study was either designed for non-random sampling or reported that non-random sampling 
occurred; (e) no definition provided for what constitutes a positive detection of target pathogen; (f) no sensitivity or specificity 
information provided for assay. 
  
2
4
 
 
 
25 
 
 
Table 1.3. Summary of the prevalence of Feline Calicivirus in shelter cat populations in studies published from January 1990 to 
February 2014. 
Country/ 
Region 
Sampling site Test Target 
RP 
(%) 
n 
Age 
distribution 
%  with 
FURD 
CI
1
 Reference 
Canada/ 
Vancouver 
Conjunctival/ 
oral-nasal  
PCR ORF 1 2.8 250 6 mo -8yr 43 a,e,f 
Gourkow et al, 
2013 
USA/ 
Florida 
Blood VN Antibody 36.6 347 
>6mo - >5 
Yr 
NR f 
DiGangi et al, 
2012 
USA/ 
California 
Conjunctival/ 
deep laryngeal 
PCR ORF 1 12.9 101 NR 76.9 a 
Burns et al, 
2011 
Belgium/ 
Liege 
Oral  RT-PCR p30 + VP1  43.1 299 2-180 mo NR e,f 
Zicola et al, 
2009 
Korea/ 
Yangju 
Conjunctival/ 
oro-pharynx 
PCR 
Capsid 
protein  
0 78 NR 0 d,e,f 
Kang et al, 
2008 
UK Oropharyngeal VI CPE 28 116 NR NR c,f 
Coyne et al, 
2007 
USA/ 
California 
Conjunctival/ 
oropharyngeal 
VI CPE 28.1 573 0-96+mo 56 e,f 
Bannasch et al, 
2004 
USA/ 
California 
Oropharyngeal VI CPE 52.4 42 NR NR f 
Foley et al, 
2002 
Abbreviations: PCR, Polymerase Chain Reaction; VN, Viral Neutralization; VI, Virus Isolation; CPE, Cytopathic Evidence; RP, 
Reported Prevalence; Se, Sensitivity; Sp, Specificity; TP, True Prevalence; n, number of cats tested; CI, Critical Issues; NR, Not 
Reported.  
1
Critical issues: (a) no study definition of FURD was reported; (b) study had unclear explanation of inclusion criteria for cats and 
therefore selection bias could not be determined; (c) disease status was determined by more than one observer with no reporting of 
measures of inter-observer agreement; (d) study was either designed for non-random sampling or reported that non-random sampling 
occurred; (e) no definition provided for what constitutes a positive detection of target pathogen; (f) no sensitivity or specificity 
information provided for assay.   
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Table 1.4. Summary of the prevalence of Chlamydophila felis in shelter cat populations in studies published from January 1990 to 
February 2014. 
Country/ 
Region 
Sampling site Test Target RP(%) Se Sp TP
1
 n 
Age 
distribution 
%  with 
FURD 
CI
2
 Reference 
Canada/ 
Vancouver 
Conjunctival/ 
oral-nasal  
PCR OmpA 0.4 1 0.99 0.39 250 6 mo -8 yr 100 a,e,f 
Gourkow et 
al, 2013 
USA/ 
California 
Conjunctival/ 
deep laryngeal 
PCR OmpA 0.01 1 0.99 0 101 NR 0 a 
Burns et al, 
2011 
Germany Conjunctival  PCR NR 35 1 0.99 35.34 20 3 mo - 16 yr NR d,e,f 
Hartmann et 
al, 2010 
Korea/ 
Yangju 
Conjunctival/ 
oro-pharynx 
PCR 
Outer 
membrane  
0 1 0.99 -0.01 78 NR 0 d,e,f 
Kang et al, 
2008 
USA/ 
California 
Conjunctival/ 
oropharyngeal 
PCR NR 2.8 1 0.99 2.82 573 0-96+ mo 82 e,f 
Bannasch et 
al, 2004 
Abbreviations: PCR, Polymerase Chain Reaction; VN, Viral Neutralization; VI, Virus Isolation; CPE, Cytopathic Evidence; RP, 
Reported Prevalence; Se, Sensitivity; Sp, Specificity; TP, True Prevalence; n, number of cats tested; CI, Critical Issues; NR, Not 
Reported.  
1
TP falls between 0 and 100% and as such any values calculated as <0 or >100% should be considered to be 0 or 100% respectively.  
2
Critical issues: (a) no study definition of FURD was reported; (b) study had unclear explanation of inclusion criteria for cats and 
therefore selection bias could not be determined; (c) disease status was determined by more than one observer with no reporting of 
measures of inter-observer agreement; (d) study was either designed for non-random sampling or reported that non-random sampling 
occurred; (e) no definition provided for what constitutes a positive detection of target pathogen; (f) no sensitivity or specificity 
information provided for assay.   
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Table 1.5. Summary of the prevalence of Bordetella bronchiseptica in shelter cat populations in studies published from January 1990 
to February 2014. 
Country/ 
Region 
Sampling site Test Target RP (%) Se Sp TP
1
 N 
Age 
distribution 
%  with 
FURD 
CI
2
 Reference 
Canada/ 
Vancouver 
Conjunctival/ 
oral-nasal  
PCR FhaB 2.4 0.935 0.971 2.62 250 6 mo -8 yr 83 a,e,f 
Gourkow et 
al, 2013 
USA/ 
California 
Conjunctival/ 
deep laryngeal 
PCR FhaB 9.9 0.935 0.971 10.9 101 NR 80 a 
Burns et al, 
2011 
USA/ 
California 
Conjunctival/ 
oropharyngeal 
Culture 
Whole 
target 
9.5 0.152 1 62.5 573 0-96+ mo 57 e,f 
Bannasch 
et al, 2004 
USA/ 
California 
Oropharyngeal Culture 
Whole 
target 
22.22 0.152 1 146.18 45 NR NR f 
Foley et al, 
2002 
Belgium/ 
Flanders 
Nasal  Culture 
Whole 
target 
4.6 0.152 1 30.26 65 
<6mo to 
>6mo 
NR b,f 
Pasmans et 
al, 2001 
UK 
Oropharyngeal 
+/- nasal 
Culture 
Whole 
target 
19.5 0.152 1 128.29 185 1 mo – 7+yr NR d,f 
Binns et al, 
1999 
Abbreviations: PCR, Polymerase Chain Reaction; VN, Viral Neutralization; VI, Virus Isolation; CPE, Cytopathic Evidence; RP, 
Reported Prevalence; Se, Sensitivity; Sp, Specificity; TP, True Prevalence; n, number of cats tested; CI, Critical Issues; NR, Not 
Reported.  
1
TP falls between 0 and 100% and as such any values calculated as <0 or >100% should be considered to be 0 or 100% respectively.  
2
Critical issues: (a) no study definition of FURD was reported; (b) study had unclear explanation of inclusion criteria for cats and 
therefore selection bias could not be determined; (c) disease status was determined by more than one observer with no reporting of 
measures of inter-observer agreement; (d) study was either designed for non-random sampling or reported that non-random sampling 
occurred; (e) no definition provided for what constitutes a positive detection of target pathogen; (f) no sensitivity or specificity 
information provided for assay.   
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Table 1.6. Summary of the prevalence of Mycoplasma species in shelter cat populations in studies published from January 1990 to 
February 2014. 
Country/ 
Region 
Sampling site Test Target RP(%) n 
Age 
distribution 
%  with 
FURD 
CI
1
 Reference 
Canada/ 
Vancouver 
Conjunctival/ 
oral-nasal  
PCR ITS-1 21.6 250 6 mo -8 yr 39 a,e,f 
Gourkow et al, 
2013 
USA/ 
California 
Conjunctival/ 
deep laryngeal 
PCR ITS-1 25.7 101 NR 76.9 a 
Burns et al, 
2011 
Germany Conjunctival  PCR NR 25 20 3 mo - 16 yr NR d,e,f 
Hartmann et al, 
2010 
USA/ 
California 
Conjunctival/ 
oropharyngeal 
PCR 
16S 
rRNA 
14.4 573 0-96+ mo 94 e,f 
Bannasch et al, 
2004 
Abbreviations: PCR, Polymerase Chain Reaction; VN, Viral Neutralization; VI, Virus Isolation; CPE, Cytopathic Evidence; RP, 
Reported Prevalence; Se, Sensitivity; Sp, Specificity; TP, True Prevalence; n, number of cats tested; CI, Critical Issues; NR, Not 
Reported.  
1
Critical issues: (a) no study definition of FURD was reported; (b) study had unclear explanation of inclusion criteria for cats and 
therefore selection bias could not be determined; (c) disease status was determined by more than one observer with no reporting of 
measures of inter-observer agreement; (d) study was either designed for non-random sampling or reported that non-random sampling 
occurred; (e) no definition provided for what constitutes a positive detection of target pathogen; (f) no sensitivity or specificity 
information provided for assay.   
 
 
 
 
2
8
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bias occurred, while a second study utilized convenience sampling which also incurs 
selection bias [76,79].  
Three of the four studies have very similar reported prevalence and together the 
average reported prevalence is 33.47%. One study reports a prevalence of 4.1% FURD in 
the shelter population [76]. This is much lower than the other reported prevalence and 
may be explained by the fact that several shelters participating in the study did not report 
all of their cats and so selection bias was introduced. This is compounded by the fact that 
all personnel in the shelters were responsible for tracking and recording the feline 
information and so there were multiple people responsible for interpreting disease 
presence or absence.  
Critical review of the prevalence of target pathogens 
All of the pathogen target based prevalence studies received at least one critical 
comment. The majority of this is due to the fact that sensitivity and specificity of assays 
utilized in the studies were not reported and very few studies reported any validation 
steps taken to ensure assay performance. As described in above, due to this lack of 
reporting substitute sensitivities and specificities were utilized when appropriate for the 
determination of true prevalence.  
Overall 8 studies qualified for inclusion in FHV prevalence analysis, 8 studies for 
FCV analysis, 5 studies for C. felis analysis, 6 studies for B. bronchiseptica analysis, and 
4 studies for M. felis analysis. Three of these studies were included in all pathogen 
analysis [43,81,91]. The first of these studies was also utilized in the FURD prevalence 
review and did not provide a definition of FURD used in the study and utilized outside 
testing of samples through IDEXX and thus did not supply a sensitivity, specificity, or 
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definition for a positive vs negative test result[81]. The second of these studies did not 
supply a definition of FURD but did explain validation and performance requirements for 
the assays utilized as well as report Ct values for one of the PCR tests performed [91]. 
This paper also utilized outside testing through IDEXX reference laboratories but overall 
this paper had a much more thorough explanation of study design and methodology used 
[91]. The final overarching study had shelter personal select cats for inclusion in the 
study as cases and controls were then randomly selected which could lead to selection 
bias[43]. This study also utilized a mixture of bacterial culture, viral isolation, and PCR 
for identification of the different targets. While there is explanation for culture and viral 
results, there is no definition of PCR positive results or internal validation of the testing 
platforms[43].  
Three studies included three of the target pathogens [92-94]. Hartmann et al. 
(2010) included the targets FHV, C. felis, and Mycoplasma species. The multiplex qPCR 
assay was previously utilized in a publication but no validation data was provided for the 
sensitivity and specificity of the assay for detection of FHV and C. felis [92].  They do 
perform a comparison between the Immunofluorescence Assay(IFA) and qPCR for C. 
felis but do this with the unknown clinical samples and thus the comparison does not 
serve as a validation of either method. The Mycoplasma species assay was sourced from 
a previous publication where validation of the assay was performed. Additionally there is 
no explanation of what constitutes a positive detection. Finally this study only included 
cats with clinical signs of conjunctivitis and selection bias occurred [92]. Foley et al. 
(2002) included the targets FHV, FCV, and B. bronchiseptica. This study was very 
complete in its methodology and all cats present at the time of sampling were included so 
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no selection bias occurred [93]. The study did not report sensitivity or specificity for the 
target isolation [93]. Kang et al. (2008) included the targets FHV, FCV, and C. felis. Cats 
were included in the study prior to euthanasia and were not a random sampling of the 
population[94]. In addition to selection bias, there was no definition of a positive target 
detection and sensitivity and specificity of the assays utilized were not reported [94]. 
 Both DiGangi et al. (2012) and Zicola et al. (2009) reported prevalence for both 
FHV and FCV targets. Neither study reported sensitivity and specificity of the platforms 
used and Zicola et al. (2009) also failed to report what constituted a positive detection. 
While both studies randomly selected cats included in the study, selection bias was 
introduced in Zicola et al. (2009) as only cats in isolation were included in the study 
[80,95].  
Three studies only reported on a single target. Coyne et al. (2007) reported on the 
prevalence of FCV in a single UK shelter, had several observers reporting FURD scores, 
and did not report the sensitivity and specificity of the viral isolation used for isolation 
[96]. Two of these studies only reported on B. bronchiseptica prevalence [49,97].  
Neither of these studies reported sensitivity and specificity of their assays. Pasman et al. 
(2001) had unclear inclusion criteria for their cat population and Binns et al. (1999) 
utilized convenience sampling to recruit a non-random sampling of the cat population.   
Discussion 
 Overall the prevalence of FURD reported in the studies included in this review 
ranged from 4.1-36.8% with 3 out of the 4 studies reporting very similar prevalence. The 
mean FURD prevalence was 26.13% (95% CI: 25.72, 26.53). This suggests that 1 out of 
every 3 cats coming into a shelter may either be entering with FURD already present or is 
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at risk of developing FURD. This also explains why FURD is such a burden on shelters 
as 1 out of every 3 cats in a shelter may require additional treatment, time in isolation, 
increased time in the shelter prior to adoption, and increased costs associated with all of 
those factors. Table 1.7. provides a summary for FURD and all of the targets and their 
RPs and calculated TPs along with 95% confidence intervals.  
Table 1.7.  Summary of average prevalence for FURD and each pathogen target both 
reported and calculated true prevalence with 95% confidence interval.   
 RP TP 
  95% CI  95% CI 
FURD 26.13 (25.72, 26.53) NP NP 
FHV 29.09 (27.76, 30.42) 36.85 (35.15, 38.56) 
FCV 25.49 (24.62, 26.26) NP NP 
C. felis 7.64 (6.70, 8.58) 7.71 (6.76, 8.66) 
B. bronchiseptica 11.35 (10.91, 11.80) 63.46 (60.03, 66.89) 
M. felis 21.68 (21.34, 22.01) NP NP 
Abbreviations: RP, reported prevalence; TP, true prevalence; , mean; CI, confidence 
interval; NP, not performed.  
 
 FHV prevalence ranged from 0 to 78.2% with a mean reported prevalence of 
29.09% and a mean calculated true prevalence of 36.85%. FCV prevalence ranged from 0 
to 52.4% with a mean reported prevalence of 25.49%. C. felis prevalence ranged from 0 
to 35% with a mean reported prevalence of 7.64% and a calculated mean true prevalence 
of 7.71%. B. bronchiseptica prevalence ranged from 2.4 to 22.22% with a mean reported 
prevalence of 11.35% and a calculated mean true prevalence of 63.46%. M. felis 
prevalence ranged from 14.4 to 25% with a mean reported prevalence of 21.68%. 
 Overall, FHV and FCV were the most prevalent pathogens detected in shelters 
with M. felis being the next most prevalent. These results for FHV and M. felis 
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correspond with previous reports describing the nature of these pathogens as being 
endemic within cat populations. This high a prevalence of FCV may also indicate that 
FCV is endemic within feline shelter populations. The large difference in reported 
prevalence and true prevalence for B. bronchiseptica is explained by the fact that the 
majority of studies utilized bacterial culture for identification of the pathogen. While 
bacterial culture is very specific for this pathogen it is poorly sensitive and thus the 
reported prevalence markedly under-reports the true prevalence of the pathogen. C. felis 
has the lowest prevalence in shelters. This is also consistent with what has been 
previously published about this pathogen and the fact that it is an obligate intracellular 
bacteria that requires close contact to be spread would limit it’s prevalence within shelter 
populations unlike the viruses.  
 Overall, while studies ranged from having one to three critical issues. Critical 
issues included several studies with selection bias, studies with inter-observer reliability 
and agreement issues, and the lack of specific definitions for upper respiratory disease as 
well as positive pathogen detection. Even fewer studies reported internal or external 
validation of their chosen testing methods and none reported sensitivities and specificities 
for the assays. While all these critical issues were present, the fact that 3 out of 4 studies 
had reproducible FURD reported prevalence of around 30% suggest that this may be 
close to the actual prevalence in shelter populations. The pathogens all had much wider 
ranges and variations in reporting detection. This can be due to the multiple different 
testing platforms used, the time of sampling of the population, and whether selection bias 
occurred and which portion of the population was selected as clinically ill animals would 
be expected to be shedding higher viral and bacterial loads.  
34 
 
 
 This review demonstrates how important it is to not only report validation of 
assay platforms used in studies and the methodology for study population selection but 
also the need to assess the body of work on a subject and address issues that have 
occurred previously in order to improve the quality of future research. 
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Abstract  
Mycoplasma species are rather ubiquitous in nature, traditionally considered to be 
animal host specific (e.g. Mycoplasma felis being associated with respiratory and ocular 
disease in cats). Recent publications have reported increased detections of multiple 
atypical Mycoplasma species in domestic animals and repeated zoonotic transmissions 
between humans and domestic animal species suggesting less host specificity than 
previously appreciated. This study investigated the hypothesis that Mycoplasma species 
occur in the cat at higher levels of diversity than previously appreciated utilizing the 
unique molecular based Pan-Myco SYBR qPCR assay for the detection of the 
Mycoplasma genus. This assay was applied to 592 feline upper respiratory tract samples 
from the conjunctiva, nares, and oro-pharyngium of 190 cats. Mycoplasma species 
identification was performed via sequencing and BLAST analysis on PCR amplicons. 
Overall, 15 Mycoplasma species were detected including: M. gateae/canadense/arginini 
cluster, M. canis, M. hyorhinis, M. alkalescens, M. cynos, M. faucium, M. dispar, M. 
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buccale, M. spumans, M. hominis, M. bovis, M. bovoculi, M. maculosum/leopharyngis 
cluster, 2 new unknown species, and Acholeplasma laidlawii. Twelve of these 
Mycoplasma species were previously unreported in cats and 2 of these previously 
unreported Mycoplasma species are known zoonotic species with M. canis and M. bovis 
both being transmitted to  and causing disease in humans. Of the 15 Mycoplasma species 
detected in cats in this study, 7 are known to be zoonotic species causing disease in 
humans. 
Introduction  
Mycoplasma species are prokaryotic organisms from the class Mollicutes which 
lack a cell wall and survive on host mucosal surfaces where they can act as primary 
pathogens, secondary pathogens, or commensals. While Mycoplasma species may reside 
in more than one host, their persistence and correlation with disease is considered to be 
host specific [1].  Several host specific Mycoplasma species are associated respiratory 
disease syndromes including Mycoplasma pneumonia in humans [2], Mycoplasma 
pulmonis in mice and rats [3], Mycoplasma cynos in domestic dogs [4], Mycoplasma 
bovis and Mycoplasma mycoides subspecies mycoides Small Colony in cattle [1], 
Mycoplasma capricolum subspecies capripneumoniae in small ruminants [1], and 
Mycoplasma hyopneumonia in pigs [5].  
In domestic cats Mycoplasma felis [6-8], Mycoplasma gateae [6-9], Mycoplasma 
argininei [10,11], and Mycoplasma feliminutum [8,12] are commonly isolated, through 
culture and detected via molecular methods, from the upper respiratory tracts of cats with 
and without Feline Upper Respiratory Disease (FURD). Mycoplasma felis, M. gateae, 
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and M. feliminutum are considered host specific. Of these, Mycoplasma felis is 
considered the most pathogenic species in domestic cats and the etiology of conjunctivitis 
and FURD [13,14]. Experimentally these diseases have been reproduced through ocular 
conjunctiva and nasal challenge[14]. However, Mycoplasma felis has also been detected 
through culture and isolation from the mucosal surfaces of clinically healthy cats most 
likely representing some form of a carrier state [7,15]. Mycoplasma gateae, as 
characterized through both culture and DNA identification, is considered a commensal in 
cats [7,9] however investigation into its ability to cause disease in cats has not been 
determined [7,16].  Mycoplasma arginine, as identified by culture, is also considered a 
commensal in cats, is isolated more often than M. feliminutum, and failed to cause disease 
on its own [11]. Mycoplasma felis has been transmitted between cats and humans as a 
zoonosis resulting in cellulitis and septic arthritis [17,18]. Mycoplasma arginini was 
implicated in zoonotic transmission, in an immune-compromised man who had a history 
of being employed in a slaughter-house facility, leading to a fatal Mycoplasmal 
septiciemia [19].  
The diversity of Mycoplasma species that have been detected in the feline upper 
respiratory tract previously, and those methods of detection, are summarized in Table 2.1. 
Mycoplasma lipophilum/hyopharyngis, M. cynos, M. pulmonis, M. arthritidis, M. 
gallisepticum and Acholeplasma laidlawii have been detected but are not considered host 
adapted to cats (Table 2.1). Aside from atypical Mycoplasma species occurring in the cat, 
the feline host specific species, M. felis, is reported as a causative agent of respiratory 
disease in race-horses [20].  Mycoplasma pneumoniae, a human host specific species, has 
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been documented in a transmission cycle from humans to hamsters and zoonotically back 
to humans [21] and Mycoplasma salivarium, also a human and primate host specific 
species, has been detected in both horses and swine samples suggesting transmission 
from humans to these domestic animal species [22,23]. Mycoplasma bovis, Mycoplasma 
canis, and Mycoplasma maculosum have also been involved in presumptive transmission 
to humans from animal hosts (zoonosis) [24-26]. 
 The detection of multiple atypical Mycoplasma species in the cat, repeated 
zoonotic transmissions, and various transmissions between domestic species suggests less 
host specificity than previously appreciated.  In the feline upper respiratory tract, the 
limited number of Mycoplasma species detected may be due in large part to detection 
methods utilized and study sample size [6,7,10,11,27].  
Table 2.1. Mycoplasma Species Previously Reported in the Feline Upper Respiratory 
Tract, Their Primary Host, Their Host Specificity, and the Method of Previous 
Isolation/Detection.  
Mycoplasma species Primary Host 
Host 
Specificity
a
 
Detection Method 
M. felis[6-8]
b
 Felid Y 
Culture, Serology, 
PCR 
M. gateae/canadense[7-10] Multiple N 
Culture, Serology, 
PCR 
M. feliminutum[8,12] Felid Y Culture, PCR 
M. arginini
b
[10,11] Multiple N Culture, PCR 
M. lipophilum/hyopharyngis[6] Hominid/Porcids Y PCR 
M. cynos[6] Canid Y PCR 
M. pulmonis[7] Rodent Y Culture, Serology 
M. arthritidis[7] Rodent Y Culture, Serology 
M. gallisepticum[7] Poultry Y Culture, Serology 
Acholeplasma laidlawii[7] Soil N Culture, Serology 
a Specificity for the primary host as indicated by ‘N’  to demonstrate that the Mycoplasma 
species is not considered host specific and ‘Y’ for Mycoplasma species that are 
considered host specific. 
b
 Mycoplasma species which have previously reported zoonotic transmissions.  
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Traditionally, Mycoplasma species were detected via cultivation in tissue culture 
and this technique can be sensitive for the isolation of some Mycoplasma species; 
however, in general culture has been found a poor and inconsistent method for isolating 
and identifying these organisms. The disadvantages of tissue cultivation include the large 
number of Mycoplasma species that: are uncultivable by current methodologies, have 
similar colony morphology, grow in mixed colonies [28] , and/or require an extended 
length of time for colony growth which allows for overgrowth of other bacteria.  
Alternately,  molecular methods such as conventional Polymerase Chain 
Reactions (PCR) and real-time PCR (qPCR) assays have been developed for the specific 
detection of Mycoplasma felis [29,30], M. bovis [31], M. hyopneumonia [32], and others. 
Initially conventional PCR offered more rapid and specific detection than traditional 
culture; however this method suffered from sensitivity issues and the need for labor and 
time consuming electrophoresis for detection of positives. Advantages of qPCR include: 
being more rapid, sensitivity, and specific based on fluorescent probes used to detect 
positives in real-time. With the improved sensitivity and specificity of the probe based 
assay comes disadvantages which include the identification of missing subspecies with 
gene mutations and pathogen evolution events. The qPCR assays also have limited 
application in detection of atypical Mycoplasma species due to their high level of 
specificity. This restricts their use in studies designed to investigate the diversity of 
Mycoplasma species occurring in a host.  
This study utilized a unique molecular based SYBR GREEN qPCR assay for the 
detection of the Mycoplasma genus in the feline host to investigate the hypothesis that 
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Mycoplasma species occur in the cat at a higher level of diversity than previously 
appreciated. Reported here is the detection of 12 Mycoplasma species that had not been 
previously reported in the cat using the Pan-Myco SYBR qPCR assay. Two of these 
species were previously reported to be zoonotic and 2 were unknown species. Of the 15 
Mycoplasma species detected in cats overall in this study 7 were reported zoonotic 
agents. 
Materials and Methods 
Mycoplasma Strains and Colony Forming Unit Determination 
Mycoplasma felis strain 23391and Mycoplasma gateae strain 23392 (American 
Tissue Culture Collection, Manassas, VA) were reconstituted from lyophilized culture 
stocks in Friis Broth (Kindly provided by Dr. Ricardo Rosenbusch, Iowa State 
University, Ames, IA) and Mycoplasma bovis strain 25025(American Tissue Culture 
Collection, Manassas, VA) was reconstituted in Brain Heart Infusion Broth(BBL, Becton, 
Dickerson and Company, Sparks, MD).  Concentrated stocks were stored at -80
o
C in 40% 
glycerol stocks and quantitated by colony forming unit determination on Mycoplasma 
agar (California, Davis).  
Clinical Feline Samples  
 Five hundred and ninety two samples were collected from cats residing in 5 
different animal shelters and visiting the Lloyd Veterinary Medical Center. At the time of 
sampling all cats were evaluated for clinical signs of FURD including conjunctivitis, 
ocular and nasal discharge, sneezing, and oral stomatitis and faucitis and documented as 
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having the presence or absence of FURD. Conjunctival, nasal, and deep oropharynx 
samples were collected using dry sterile nylon flocculated swabs placed into an Amies 
medium collection system (Copan ESwab 480C and 481C, Copan Diagnostics Inc, CA) 
and chilled for transport. At the laboratory samples were stored at -80
o
C until processing. 
The sampling of cats for this experiment was approved by the Iowa State University 
Institutional Animal Care and Use Committee.  
Nucleic Acid Extraction  
Nucleic acid extraction was performed using a commercial spin column extraction 
kit (DNeasy Blood & Tissue Kit and Quick-Start Protocol, QIAGEN, Valencia, CA). All 
stocks and clinical samples were defrosted at 4
o
C for 24 hours and mixed thoroughly via 
pulse vortex prior to extraction. Procedures followed the kit protocol for non-nucleated 
blood, with the following modifications: 100ul of sample was used during lysis and 
incubated for 5 minutes at 56
o
C, during the final wash samples were centrifuged for 6 
minutes at16.3 g force, and nucleic acid was eluted into 100ul of the provided buffer 
preheated to 56
o
C. Each extraction of clinical samples included a M. felis positive and a 
phosphate buffered saline (HyClone, Thermo Scientific, Logan, UT) negative control. 
Pan-Myco SYBR qPCR assay 
Pan-Myco SYBR qPCR was performed for Mycoplasma species with the forward 
primer, MYCP 3a, 5’-CATATGTTCTTTGAAAACTG-3’, and the reverse primer, 
MYCP 4, 5’-GCATCCACCAAAAACTCT-3’.  These primer sets were originally 
developed for M. bovis detection  using conventional  nested PCR [31] and  modified for 
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the Pan-Myco SYBR GREEN PCR[40].  For the qPCR, a reaction volume of 12uL 
comprised of 2X PerfeCTa SYBR Green FastMix (Quanta Biosciences, Gaithersburg, 
MD), forward and reverse primers at .208 uM (Integrated DNA Technologies, Coralville, 
IA), 2ul of extracted nucleic acid, and PCR-grade H2O was utilized. Thermocycling 
conditions performed on a real-time PCR system (Bio-Rad Laboratories, Hercules, CA) 
were 95
o
C for 2 min, followed by 40 cycles of 94
o
C for 30 sec, 55
o
C for 2 min, and 72
o
C 
for 60sec with fluorescence read in the FAM channel during annealing and extension 
(Figure 1.1). qPCR was immediately followed by melt analysis which included stepwise 
heating of the block from 55
o
C to 85
o
C progressing at an increment of 0.1
o
C per 10 sec 
with fluorescence read at each increment. Melt analysis was preceded by the 95
o
C for 
15sec, and 55
o
C for 6 sec. Melt analysis was used to generate a dissociation curve and 
determination of the amplicon melting temperature (Tm) (Figure 1.2 and 1.3). 
Assay Limits of Detection and PCR Processing of Clinical Sample 
 
Serial dilutions in triplicate of stock M. felis and M. gateae DNA were run for 
assay validation, limits of detection, and determination of melt temperature on the Pan-
Myco SYBR qPCR.  Clinical samples were run in duplicate wells and each plate 
contained both a stock M. felis positive control and a PCR-grade H2O negative control. 
Samples which crossed the amplification threshold (Ct) and had a Tm between 68-75
o
C 
are positive for Mycoplasma species.   
Mycoplasma species detected by the Pan-Myco SYBR qPCR 
  Definitive identification of Pan -Myco SYBR qPCR generated amplicons was 
performed through direct Sanger sequencing (DNA Sequencing Facility, Iowa State 
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Figure 1.1. Amplification Curve of the Three Positive Control Mycoplasma Species.  
The Pan-Myco PCR primer set 
binds to a conserved region of the 
Mycoplasma genome flanking 
species identifying sequences. 
PCR generates double stranded 
DNA (dsDNA) with bound SYBR 
GREEN dye, rising fluorescence 
is detected by the thermocycler 
and demonstrated here with 
Mycoplasma felis(solid line), 
Mycoplasma gateae(circles), and 
Mycoplasma bovis (triangles). 
 
 
Figure 1.2. Dissociation Curve of 
the Three Positive Control 
Mycoplasma Species.  
Incremental increasing in 
temperature causes the melting of 
the dsDNA into single stranded 
DNA (ssDNA) and results in a 
dissociation curve demonstrated 
here with Mycoplasma felis (solid 
line), Mycoplasma gateae 
(circles), and Mycoplasma bovis 
(triangles). 
                                      
 
Figure 1.3. Determination of Melting 
Temperature for the Three Positive 
Control Mycoplasma Species.  
Incremental increases in temperature 
causes the DNA binding dye to be 
released. The specific temperature is 
determined by changes in 
fluorescence in relation to time. Melt 
temperature (Tm) is dependent on 
amplicon size and GC content and 
differs between Mycoplasma species 
as demonstrated here with 
Mycoplasma felis (solid line), Mycoplasma gateae (circles), and Mycoplasma bovis 
(triangles).  
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University, Ames, IA). Samples with a single amplicon were sent for sequencing with 
forward Pan-Myco SYBR qPCR primers. Samples with 2 or more Mycoplasma species 
present were visualized and separated with gel electrophoresis in 2% low melt agarose 
(Lowmelt, Bio-Rad Laboratories, Hercules, CA). Each gel was pre-stained with nucleic 
acid gel stain (Gel Star Nucleic Acid Gel Stain, Lonza, Rockland, ME) and included a 
well of 100bp DNA Ladder (Invitrogen Life Technologies Co, Carlsbad, CA) , M. felis 
positive control, and negative control. A 10X BlueJuice loading dye (Invitrogen Life 
Technologies Co, Carlsbad, CA) was used and electrophoresis was performed at 120 
volts for 60 minutes.  Amplicons between 50 and 300 base pairs were excised from the 
gel, purified using a commercial kit for gel purification (QIAquick Gel Extraction Kit and 
the Quick-StartProtocol, QIAGEN, Valencia, CA), and the resulting DNA extraction was 
sent for sequencing as previously described. 
The resulting amplicon sequence was subjected to BLAST, and alignments with a 
high level of query coverage (greater than 80%) and maximum identities (greater than 
95%) with a known referenced or commercially available Mycoplasma species in 
GenBank served as definitive species identification when possible. 
Results 
Validation and Limits of Detection of Pan-Myco SYBR qPCR for Stock Mycoplasma 
Species  
Validation of the Pan-Myco SYBR qPCR assay was performed using pure culture 
stock Mycoplasma felis, Mycoplasma gateae, and Mycoplasma bovis (American Tissue 
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Culture Collection, Manassas, VA). The standard curve for M. gateae had a R
2
 of 0.996 
and an amplification efficiency of 78% and a Tm of 70.9
o
C (SE=0.18) (Figure 1.4). The 
standard curve for M. felis was determined to have an R
2
 of 0.996 and an amplification 
efficiency of 121% (data not shown). The Pan-Myco PCR Assay successfully amplified 
all three stock Mycoplasma species and could differentiate species based on the Tm of 
the qPCR amplicon (Figure1.1, 1.2, and 1.3). The mean Tm for M. felis was determined 
to be 70.4
o
C (SE=0.14) and the mean Tm for M. bovis was 72.3
o
C (SE =0.30).  The assay 
primers amplified a 16s area corresponding to 180 base pairs for M. gateae, 200 base 
pairs for M. felis, and 220 base pairs for the M. bovis (Figure 1.5). The limits of detection 
for the Pan-Myco SYBR qPCR for M. gateae and M. felis were equivalent to 1 CFU. The 
Pan-Myco SYBR qPCR limits of detection for genome equivalents based on taqman 
qPCR[29] in droplet digital PCR[33]  was .3 genome equivalents for M. felis. 
 Figure 1.4. Mycoplasma gateae Standard Curve on 
the Pan-Myco SYBR qPCR Assay.  
This graph demonstrates the standard curve for the 
M. gateae pure culture control which was utilized to 
validate the Pan-Myco SYBR qPCR assay. 
Standard curve was created via the running of a 
serial dilution set of the standard DNA in triplicate. 
The standard curve demonstrates an R
2
 of 0.996 and 
an amplification efficiency of 78%.  
Figure1. 5. Agarose Gel Electrophoresis 
of Pan-Myco SYBR qPCR Amplicons 
for Control Species.  
This photographs of a agarose gel 
electrophoresis shows lane 1 containing 
a 200 bp amplicon for stock 
Mycoplasma felis species with a Tm of 
70.4, lane 2 containing a 180 bp 
amplicon for stock Mycoplasma gateae species with a Tm of 70.9, lane 3 with a 220 bp 
amplicon for stock Mycoplasma bovis species with a Tm of 72.3, and lane 4 containing a 
100bp molecular marker.  
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Mycoplasma Species Detected in Clinical Samples 
 Fifteen species of Mycoplasma and 1 species of Acholeplasma were detected in 
feline clinical samples utilizing the Pan-Myco SYBR qPCR assay. These include 3 
species previously reported in cats (Mycoplasma arginini/canadense/gateae cluster, 
Mycoplasma leopharyngis/maculosum cluster, and Mycoplasma cynos), 10 species 
previously unreported in cats (Mycoplasma buccale, Mycoplasma facium, Mycoplasma 
dispar, Mycoplasma hyorhinis, Mycoplasma bovis, Mycoplasma hominis, Mycoplasma 
spumans, Mycoplasma alkalescens, Mycoplasma canis, Mycoplasma bovoculi), and two 
unknown Mycoplasma species. The two unknown species had sequences that attained 
low identity matches with GenBank (FR799684.1 and FR799683.1) and were stated as 
unculturable Mycoplasma species from the intestines of fish.  Table 2.2 provides a list of 
Mycoplasma species detected with the corresponding GenBank accession numbers that 
were used for definitive identification of the species based upon percent homology 
(expressed as percent query coverage and percent maximum identity). Amplicon size as 
determined by electrophoresis and Tm determined by dissociation curve analysis 
following Pan-Myco SYBR qPCR are also reported as well as the anatomic location of 
detection and the percent positive samples. 
Mycoplasma arginini/canadense/gateae cluster was the most commonly detected 
species and occurred in 7.77% of the samples, of which 37 of the 46 positive sequences 
were obtained from the oral cavity. This Mycoplasma species (M. 
arginini/canadense/gateae) is reported as a cluster due to the limited variability of the 
16s intergenic region of the Mycoplasma genus that the Pan-Myco SYBR qPCR assay 
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amplifies. Similarly, Mycoplasma leopharyngis and Mycoplasma maculosum had a 99% 
identity in this amplified region and are also reported as a cluster. The Mycoplasma 
leopharygnis/maculosum cluster occurred in 1.01% of the samples and Mycoplasma 
spumans was detected in 2.03% of the samples. Additionally, Acholeplasma laidlawii 
was detected with the Pan-Myco SYBR qPCR assay. While A. laidlawii is not a 
Mycoplasma species, it is a member of the class Mollicutes and the amplicon generated 
had 24.2% homology with the 16S ribosomal RNA of the M. felis amplicon. Other 
Mycoplasma species were considered rare detections and occurred in less than 1% of the 
samples. These comprised the majority of the species detected (13 out of 15). Of the 592 
samples screened with the Pan-Myco SYBR qPCR assay 12.3% had 1 or more 
Mycoplasma species detected. The melt temperatures determined by the SYBR GREEN 
ranged from 69.5
o
C to 73.5
o
C some of which overlapped with multiple Mycoplasma 
species while others were unique. While the Pan-Myco SYBR qPCR assay allowed for 
the detection of atypical and rare Mycoplasma species events in cats it also allowed for 
the detection of more than one Mycoplasma species in a single sample.  
 Ten of the samples collected included concurrent detection of 2 or more 
Mycoplasma species. Table 2.3 demonstrates the anatomical site of origin, whether 
FURD was present or absent in the cat the sample was obtained from, and the 
Mycoplasma species that were detected in the sample. In this table, Mycoplasma gateae 
and Mycoplasma leopharyngis are used to represent their respective clusters. Three 
samples contained 3 Mycoplasma species, while 7 samples contained 2 Mycoplasma 
species. Of the species involved in co-detection, 60% of the samples contained the
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Table 2.2. Mycoplasma Species Detected in Feline Clinical Samples Using the Pan-Myco SYBR qPCR Assay.  
Mycoplasma species GenBank
a
 % Homology Amplicon size
d
 Tm
e
 Anatomic location 
% Positive 
cases
f
 
  A
b
 B
c
   Oral Nasal Ocular  
M. arginini JN935883.1         
M. canadense AY800341.1 88-99 94-100 180 BP 70.7-72.7 37 3 6 7.77 
M. gateae AY973562.1         
M. leopharyngis AY762644.1 81-99 84-97 220 BP 71.8 2 1 3 1.01 
M. maculosum AF443610.1         
M. spumans AF538684.1 92-100 92-100 200 BP 71.7-72.5 2 1 9 2.03 
M. alkalescens AY816348.1 96-99 98-99 ND 71.4-72.2 0 1 2 <1 
M. canis AF443605.1 96-99 97-98 ND 71.9-72.1 1 0 2 <1 
M. cynos AF538682.1 95-97 88-99 200 BP 72.4 1 0 2 <1 
M. buccale AY796064.1 94 92 190 BP 71.9 0 1 0 <1 
M. faucium AY800342.1 100 100 ND 72.2 0 0 1 <1 
M. dispar DQ840510.1 99 97 ND 69.5 0 0 1 <1 
M. hyorhinis CP003914.1 98 99 220 BP 71.5-72.5 1 0 1 <1 
M. bovis AY566217.1 98-99 99-100 250 BP 72.6-73.9 1 0 2 <1 
M. hominis FP236530.1 95 100 160 BP 71.3 1 0 0 <1 
M. bovoculi AY785380.1 99 99 ND 71.7 0 0 1 <1 
Uncultured sp.  FR799684.1 89 82 200 BP 73.2 0 1 0 <1 
Uncultured sp.  FR799683.1 91 93 ND 73.5 0 0 1 <1 
A. laidlawii CP000896.1 83 100 100 BP 71.8 0 0 1 <1 
a
 GenBank Accession number identified through BLAST analysis of amplicon sequences 
b
 Percent Query Coverage (>80% considered definitive Mycoplasma detection), ranges reported span the query coverage from 
multiple positives 
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Table 2.2 footnotes continued… 
c
 Percent Maximum Identity (>95% considered definitive Mycoplasma detection), ranges reported span the maximum identity from 
multiple positives 
d
 Amplicon size in base pairs acquired through gel electrophoresis when performed, ND = Not Done 
e 
Tm determined by post-qPCR dissociation curves, the ranges are reported for multiple positives 
f
 Percent of occurrences of the Mycoplasma species identified out of 592 samples.  
 
Table 2.3. Detection of Multiple Mycoplasma Species Concurrently in Individual Cat Samples by the Pan-Myco SYBR qPCR Assay.  
Sample type FURD status
a
 Mycoplasma species detected No. of Mycoplasma species 
Nasal P M. alkalescense M. buccale M. leopharygis
b
 3 
Oral P M. gateae
b
 M. leopharygis M. spumans 3 
Ocular P M. gateae M. spumans M. bovis 3 
Ocular P M. dispar M. hyorhinis 2 
Ocular P M. gateae M. maculosum 2 
Oral P M. gateae M. leopharygis 2 
Ocular A M. leopharygis M. spumans 2 
Ocular A M. gateae A. laidlawii 2 
Oral A M. gateae M. hominis 2 
a 
Feline upper respiratory disease P = present, A = absent 
b 
Denotes that these Mycoplasma species are members of a previously discussed cluster; for M. leopharyngis this includes M. 
maculosum, for M. gateae this cluster includes M. arginini and M. canadense 
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Mycoplasma gateae cluster. All of the samples with 3 Mycoplasma species detected came 
from cats with FURD, while 57.14% of the samples with dual detections came from cats 
with FURD. Ocular conjunctival swabs comprised 60% of the samples, while 30% were 
deep oro-pharyngeal swabs, and a single swab came from the nasal planum. Along with 
reporting the co-occurrence of Mycoplasma species in a single anatomical location, the 
Pan-Myco SYBR qPCR in conjunction with holistic upper respiratory sampling allowed 
for the reporting of the ecology of upper respiratory Mycoplasma species in individual 
cats.  
 Fourteen of the 190 cats tested (7.37%) had multiple Mycoplasma species 
concurrently detected from their collection of samples. In Table 2.4 the anatomical 
distribution of Mycoplasma detection, the occurrence in individual cats, whether those 
cats had FURD, and the species present samples from those cats are demonstrated. Again, 
Mycoplasma gateae and Mycoplasma leopharyngis are used to represent their respective 
clusters. Three of the 14 cats (21.4%) had 3 Mycoplasma species detected from their 
collection of samples. 21.4% of the cats with multiple Mycoplasma species detected 
concurrently in multiple anatomical locations had FURD. All but 1 of the cats (92.86%) 
had the Mycoplasma gateae cluster detected in a sampling location.  
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Table 2.4. Distribution and Speciation of Multiple Mycoplasma Species Occurring 
Concurrently in Individual Felids.  
Samples Occurrence
a
 
% with 
FURD 
Mycoplasma species present 
Oral/Ocular/Nasal 1 0 M. gateae
b
 M. spumans 
M. 
alkalescens 
Ocular/Nasal 1 0 M. gateae 
M. 
leopharygis
b
 
M. spumans 
Oral/Ocular 1 100 M. gateae M. dispar 
M. 
hyorhinis 
Oral/Ocular 2 0 M. gateae M. cynos  
Oral/Ocular 1 0 M. gateae A. laidlawii  
Ocular/Ocular 1 100 M. gateae M. maculosum  
Oral/Ocular 1 0 M. gateae M. canis  
Oral/Ocular 3 0 M. gateae M. spumans  
Oral/Ocular/Nasal 2 50 M. gateae Uncultured sp.  
Ocular/Ocular 1 0 
M. 
spumans 
M. cynos  
a 
Occurrence of this combination in individual cats  
b 
Denotes that these Mycoplasma species are members of a previously discussed cluster; 
for M. leopharyngis this includes M. maculosum, for M. gateae this cluster includes M. 
arginini and M. canadense 
 
Discussion 
  Although Mycoplasma species have been traditionally considered host specific 
pathogens, the increasing isolation, through culture methods, and detection, through 
molecular methods, of multiple atypical Mycoplasma species in domestic animals and 
repeated zoonotic transmissions suggest less host specificity than previously appreciated. 
This study investigated the hypothesis that Mycoplasma species occur in the cat at a 
higher level of diversity than previously detected. This hypothesis was tested utilizing the 
unique molecular based Pan-Myco SYBR qPCR assay for the detection of the 
Mycoplasma genus. Application of this assay to 592 feline upper respiratory tract 
samples from 190 cats resulted in the identification of 15 Mycoplasma species including: 
M. gateae/canadense/arginini cluster, M. canis, M. hyorhinis, M. alkalescens, M. cynos, 
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M. faucium, M. dispar, M. buccale, M. spumans, M. hominis, M. bovis, M. bovoculi, M. 
maculosum/leopharyngis cluster, 2 new unknown species, and Acholeplasma laidlawii.  
The Mycoplasma species detected in this study and in previous studies are summarized in 
Table 2.5. This table includes whether detection in this study was a novel detection in 
cats, what the principal host for this Mycoplasma species is, whether the Mycoplasma is 
pathogenic in that principal host, and whether it has been previously reported as a 
zoonosis. In total, 71 (12%) of the 592 samples tested had Mycoplasma species detected 
in them with 26 of those detections (37%) being novel in the cat. 
 Overall, 15 Mycoplasma species were detected in the feline samples in this study 
with 12 (80%) of the Mycoplasma species detected being previously unreported in the 
feline upper respiratory tract. These include: M. spumans, M. canis, M. alkalescens, M. 
dispar, M. bovis, M. bovoculi, M. buccale, M. faucium, M. hominis, M. hyorhinis and two 
new unknown species. The two new unknown species had low homology to GenBank 
accessions suggesting that they are actually separate new species. Further work is 
necessary to characterize these. The most frequently detected atypical species were M. 
spumans, M. canis, M. alkalescens, and M. bovis. The majority of Mycoplasma species 
detected in this study were novel identifications in the cat demonstrating that the diversity 
of Mycoplasma species is much greater than previously appreciated. These novel 
detections in the feline host suggest that cats are capable of harboring a much broader 
range of Mycoplasma species with unknown consequences to the cat itself. Many of these 
Mycoplasma species detected are considered pathogenic in other domestic animal species 
and in humans. This finding is not completely unique as multiple studies using qPCR and 
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Table 2.5. Summary of the Mycoplasma Species Detected in this Study as well as Those 
Previously Reported in the Feline Upper Respiratory Tract.  
Mycoplasma 
species
a
 
Novel 
detection?
c
 
Principal 
Host 
Pathogenic?
d
 
Reported 
zoonosis
e
 
M. gateae
b
 N Multiple Y/N Y 
A. laidlawii N Multiple Y/N NA 
M. leopharyngis
b
 N Canid/Felid N Y 
M. spumans Y Canid Y N 
M. canis Y Canid N Y 
M. cynos N Canid Y N 
M. alkalescens Y Cattle Y N 
M. dispar Y Cattle Y N 
M. bovis Y Cattle Y Y 
M. bovoculi Y Cattle Y N 
M. buccale Y Human Y NA 
M. faucium Y Human Y NA 
M. hominis Y Human Y NA 
M. hyorhinis Y Swine Y N 
M. lipophilum
b
 ND 
Human, 
Swine 
N NA 
M. pulmonis ND Rodent Y Y 
M. arthritidis ND Rodent Y Y 
M. gallisepticum ND Poultry Y N 
M. feliminutum ND Felid N N 
M. felis ND Felid, Equid Y Y 
a 
Mycoplasma species that are underlined are those species detected in this study 
b 
Denotes that these Mycoplasma species are members of a previously discussed cluster; 
for M. leopharyngis this includes M. maculosum, for M. gateae this cluster includes M. 
arginini and M. canadense; for M. lipophilum this includes M. hyopharyngis 
c 
Novel detection of Mycoplasma species in cats, N= No, ND= Not Detected, Y = Yes  
d 
Is this Mycoplasma species considered pathogenic in its host, Y = Yes, No = No, Y/N = 
Depends upon the host and host conditions 
e 
Previously reported as zoonotic, Y = Yes, N = No, NA = Not Applicable 
 
other various high throughout sequencing methodologies and platforms [34] are 
discovering an ever increasing number of bacterial pathogens in humans that, similar to 
this study, were uncultivable yet the dominate bacterial pathogen genome present in 
diseased tissue and disease conditions such as respiratory diseases [35]. 
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The presence of previously undetected Mycoplasma species in cats that are 
significant pathogens in humans or other domestic animal species also suggests that cats 
can become infected with and harbor, apparently without disease, these Mycoplasma 
species with currently unknown consequences to both the cats and the other species.  M. 
spumans is a pathogenic Mycoplasma species in the dog causing arthritis and pneumonia, 
while M. canis is a commensal species of the canine upper respiratory tract [36]. M. 
alkalescens, M. bovis, and M. dispar are both bovine pathogenic Mycoplasma species 
causing mastitis, respiratory disease, and joint disease [1]. M. bovoculi is associated with 
ocular disease in cattle and may contribute to Bovine Infectious Keratoconjuncitivis [1]. 
Both M. bovoculi and M. bovis are pathogens of considerable concern in the cattle 
industry. M. hyorhinis causes arthritis and pneumonia in swine [1] and M. buccale, M. 
faucium, and M. hominis, are all considered human host specific Mycoplasma species 
[37]. M. buccale and M. faucium are rarely identified and are of concern in 
immunocompromised humans. M. hominis has been associated with pyelonephritis and 
pelvic inflammatory disease in humans [37].  
These findings may well be important and especially relevant to public health 
when the close relationship between cats, their human owners, and other animal species 
are considered in disease outbreaks. Not only does this data suggest that cats are capable 
of harboring multiple Mycoplasma species considered human host specific pathogens but 
many of the Mycoplasma species detected in this study have also been previously 
reported to have zoonotic capabilities and transmissions.  
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This study detected 4 Mycoplasma species in cats that have had previously 
reported zoonotic transmissions. Of these, 2 Mycoplasma species are novel detections in 
the feline host. These include M. canis, which colonized several individuals of a 
household with one person developing respiratory infection [25] , and M. bovis, was 
isolated from a woman with systemic illness including pneumonia [24]. M. arginini was 
detected in this study as part of the M. gateae cluster and is reported to have caused 
septicemia in a slaughterhouse worker [19] and M. maculosum has been reported to have 
been isolated from the cerebrospinal fluid of a patient with meningitis who was assumed 
to have contracted the Mycoplasma from his dog [26]. In previous studies, M. felis, M. 
pulmonis, and M. arthritidis have been reported in cats and all also have been reported in 
zoonotic transmissions. M. felis has caused cellulitis after a cat scratch and closed septic 
arthritis after close contact with cats [17,18]. M. pulmonis was found to be colonizing 
technicians working with research rats [38] and M. arthritidis has been isolated from 
synovial tissue of  laboratory workers [39].  
The detection of these multiple Mycoplasma species in the feline host may 
suggest that the evolved relationship leading to domestication of cats with humans may 
have established various adaptations in one or the other species and in some cases with 
unforeseen isolated disease cases and/or larger public health ramifications, especially for 
immune-compromised individuals. The rare occurrence of these Mycoplasma species in 
this study and the lack of inclusion of other FURD pathogens prevented analysis of 
association between the concurrent presence the Mycoplasma species and feline disease 
in this population. It should however be noted that there was a high concurrence between 
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multiple Mycoplasma species detected and FURD. Further investigation is warranted into 
the possibility of association and causation between rare Mycoplasma species being 
harbored in cats with disease.  
The finding of 12 novel Mycoplasma detections in cats, 2 of which are new 
species and 2 which are reported zoonotic species as well as the complete detection of 15 
species of Mycoplasma many of which are considered host specific pathogens in either 
humans or other domestic animal species support the hypothesis that that Mycoplasma 
species are not as host specific as previously assumed. The finding of multiple 
Mycoplasma species in a single site in concurrence with FURD also supports a further 
investigation into the nature of Mycoplasma colonization and whether they are 
pathogenic. This study also demonstrates the necessity sampling both the ocular 
conjunctiva and oro-pharynx when investigating Mycoplasma infection in cats. Finally, 
the broad diversity of Mycoplasma species detected in this study and the concurrent 
detections would not have been possible without a broad detection tool such as the Pan-
Myco SYBR qPCR. The Pan-Myco SYBR qPCR proved to be capable of broad detection 
of Mycoplasma species of both veterinary and public health importance in the feline host. 
References 
1. Browning GF, Marenda MS, Markham PF, Noormohammadi AH, Whithear KG 
(2010) Mycoplasma. Pathogenesis of Bacterial Infections in Animals: Wiley-
Blackwell. pp. 549-573. 
 
2. Nadal D, Bossart W, Zucol F, Steiner F, Berger C, et al. (2001) Community-acquired 
pneumonia in children due to Mycoplasma pneumoniae: Diagnostic performance 
of a seminested 16S rDNA-PCR. Diagnostic Microbiology and Infectious Disease 
39: 15-19. 
 
65 
 
 
 
 
3. Baker DG (1998) Natural pathogens of laboratory mice, rats, and rabbits and their 
effects on research. Clinical Microbiology Reviews 11: 231-+. 
 
4. Chalker VJ, Owen WMA, Paterson C, Barker E, Brooks H, et al. (2004) Mycoplasmas 
associated with canine infectious respiratory disease. Microbiology-Sgm 150: 
3491-3497. 
 
5. Thacker EL, Halbur PG, Ross RF, Thanawongnuwech R, Thacker BJ (1999) 
Mycoplasma hyopneumoniae potentiation of porcine reproductive and respiratory 
syndrome virus-induced pneumonia. Journal of Clinical Microbiology 37: 620-
627. 
 
6. Hartmann AD, Hawley J, Werckenthin C, Lappin MR, Hartmann K (2010) Detection 
of bacterial and viral organisms from the conjunctiva of cats with conjunctivitis 
and upper respiratory tract disease. Journal of Feline Medicine and Surgery 12: 
775-782. 
 
7. Tan RJS, Lim EW, Ishak B (1977) Ecology of mycoplasmas in clinically healthy cats. 
Australian Veterinary Journal 53: 515-518. 
 
8. Heyward JT, Sabry MZ, Dowdle WR (1969) Characterization of mycoplasma species 
of feline origin. American Journal of Veterinary Research 30: 615-&. 
 
9. Gray LD, Ketring KL, Tang YW (2005) Clinical use of 16S rRNA gene Sequencing to 
identify Mycoplasma felis and M-gateae associated with feline ulcerative 
keratitis. Journal of Clinical Microbiology 43: 3431-3434. 
 
10. Johnson LR, Foley JE, De Cock HEV, Clarke HE, Maggs DJ (2005) Assessment of 
infectious organisms associated with chronic rhinosinusitis in cats. Javma-Journal 
of the American Veterinary Medical Association 227: 579-585. 
 
11. Tan RJS, Lim EW, Ishak B (1977) Significance and pathogenic role of mycoplasma 
arginini in cat diseases. Canadian Journal of Comparative Medicine-Revue 
Canadienne De Medecine Comparee 41: 349-354. 
 
12. Bemis DA (1992) Bordetella and mycoplasma respiratory-infections in dogs and cats. 
Veterinary Clinics of North America-Small Animal Practice 22: 1173-1186. 
 
13. Haesebrouck F, Devriese LA, Vanrijssen B, Cox E (1991) Incidence and significance 
of isolation of mycoplasma-felis from conjunctival swabs of cats. Veterinary 
Microbiology 26: 95-101. 
 
14. Tan RJS (1974) Susceptibility of kittens to Mycoplasma felis infection. Japanese 
Journal of Experimental Medicine 44: 235-240. 
 
66 
 
 
 
 
15. Randolph JF, Moise NS, Scarlett JM, Shin SJ, Blue JT, et al. (1993) Prevalence of 
mycoplasmal and ureaplasmal recovery from traceobronchial lavages and of 
mycoplasmal recovery from pharyngeal swab specimens in cats with or without 
pulmonary-disease. American Journal of Veterinary Research 54: 897-900. 
 
16. Tan RJS, Miles JAR (1974) Incidence and significance of mycoplasmas in sick cats. 
Research in Veterinary Science 16: 27-34. 
 
17. McCabe SJ, Murray JF, Ruhnke HL, Rachlis A (1987) Mycoplasma-infection of the 
hand acquired from a cat. Journal of Hand Surgery-American Volume 12A: 1085-
1088. 
 
18. Bonilla HF, Chenoweth CE, Tully JG, Blythe LK, Robertson JA, et al. (1997) 
Mycoplasma felis septic arthritis in a patient with hypogammaglobulinemia. 
Clinical Infectious Diseases 24: 222-225. 
 
19. Yechouron A, Lefebvre J, Robson HG, Rose DL, Tully JG (1992) Fatal septicemia 
due to mycoplasma-arginini - a new human zoonosis. Clinical Infectious Diseases 
15: 434-438. 
 
20. Wood JLN, Chanter N, Newton JR, Burrell MH, Dugdale D, et al. (1997) An 
outbreak of respiratory disease in horses associated with Mycoplasma felis 
infection. Veterinary Record 140: 388-391. 
 
21. Mikola I, Balogh G, Nagy A, Matyas M, Rady M, et al. (1997) Mycoplasma 
pneumonia epidemic as a zoonosis. Case report. Magyar Allatorvosok Lapja 119: 
403-405. 
 
22. Poland J (1978) Mycoplasmas of the respiratory tract of horses and their significance 
in upper respiratory tract disease. Equine infectious diseases IV: 437-446. 
 
23. Erickson BZ, Ross RF, Bove JM (1988) Isolation of mycoplasma-salivarium from 
swine. Veterinary Microbiology 16: 385-390. 
 
24. Madoff S, Pixley BQ, Delgiudice RA, Moellering RC (1979) Isolation of 
mycoplasma-bovis from a patient with systemic illness. Journal of Clinical 
Microbiology 9: 709-711. 
 
25. Armstron.D, Yu BH, Yagoda A, Kagnoff MF (1971) Colonization of humans by 
mycoplasma-canis. Journal of Infectious Diseases 124: 607-&. 
 
26. Heilmann C, Jensen L, Jensen JS, Lundstrom K, Windsor D, et al. (2001) Treatment 
of resistant mycoplasma infection in immunocompromised patients with a new 
pleuromutilin antibiotic. Journal of Infection 43: 234-238. 
 
67 
 
 
 
 
27. Holst BS, Hanas S, Berndtsson LT, Hansson I, Soderlund R, et al. (2010) Infectious 
causes for feline upper respiratory tract disease - a case-control study. Journal of 
Feline Medicine and Surgery 12: 783-789. 
 
28. Johnson LR, Drazenovich NL, Foley JE (2004) A comparison of routine culture with 
polymerase chain reaction technology for the detection of Mycoplasma species in 
feline nasal samples. Journal of Veterinary Diagnostic Investigation 16: 347-351. 
 
29. Soderlund R, Bolske G, Holst BS, Aspan A (2011) Development and evaluation of a 
real-time polymerase chain reaction method for the detection of Mycoplasma 
felis. Journal of Veterinary Diagnostic Investigation 23: 890-893. 
 
30. Chalker VJ, Owen WMA, Paterson CJI, Brownlie J (2004) Development of a 
polymerase chain reaction for the detection of Mycoplasma felis in domestic cats. 
Veterinary Microbiology 100: 77-82. 
 
31. Baird SC, Carman J, Dinsmore RP, Walker RL, Collins JK (1999) Detection and 
identification of Mycoplasma from bovine mastitis infections using a nested 
polymerase chain reaction. Journal of Veterinary Diagnostic Investigation 11: 
432-435. 
 
32. Marois C, Dory D, Fablet C, Madec F, Kobisch M (2010) Development of a 
quantitative Real-Time TaqMan PCR assay for determination of the minimal dose 
of Mycoplasma hyopneumoniae strain 116 required to induce pneumonia in SPF 
pigs. Journal of Applied Microbiology 108: 1523-1533. 
 
33. Hindson BJ, Ness KD, Masquelier DA, Belgrader P, Heredia NJ, et al. (2011) High-
Throughput Droplet Digital PCR System for Absolute Quantitation of DNA Copy 
Number. Analytical Chemistry 83: 8604-8610. 
 
34. Erlich Y, Chang K, Gordon A, Ronen R, Navon O, et al. (2009) DNA Sudoku-
harnessing high-throughput sequencing for multiplexed specimen analysis. 
Genome Research 19: 1243-1253. 
 
35. Lamson D, Renwick N, Kapoor V, Liu Z, Palacios G, et al. (2006) MassTag 
polymerase-chain-reaction detection of respiratory pathogens, including a new 
rhinovirus genotype, that caused influenza-like illness in New York State during 
2004-2005. Journal of Infectious Diseases 194: 1398-1402. 
 
36. Chalker VJ (2005) Canine mycoplasmas. Research in Veterinary Science 79: 1-8. 
 
37. Lee G, Kim H, Park C, Chun Y, Choi H, et al. (2012) Frequency of N. gonorrheaee, 
C. trachomatis, U. urealyticum and M. hominis in pelvic inflammatory disease 
and Fitz-Hugh-Curtis syndrome. Infection and Chemotherapy 44: 362-366. 
 
68 
 
 
 
 
38. Ferreira JB, Yamaguti M, Marques LM, Oliveira RC, Neto RL, et al. (2008) 
Detection of Mycoplasma pulmonis in laboratory rats and technicians. Zoonoses 
and Public Health 55: 229-234. 
 
39. Lemcke RM (1965) A serological comparison of various species of Mycoplasma by 
an agar gel double-diffusion technique. Journal of General Microbiology 38: 91-
100. 
 
40. Justice-Allen A, Trujillo J, Goodell G, Wilson D (2011) Detection of multiple 
Mycoplasma species in bulk tank milk samples using real-time PCR and 
conventional culture and comparison of test sensitivities. Journal of Dairy Science 
94: 3411-3419. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
69 
 
 
 
 
CHAPTER 4: VALIDATION OF A PORTABLE MOLECULAR DIAGNOSTIC 
DEVICE FOR DETECTION OF PATHOGENS ASSOCIATED WITH FELINE 
UPPER RESPIRATORY DISEASE IN CATS 
 
Modified from a paper to be submitted to The Journal of Veterinary Diagnostic 
Investigation 
 
Uri Donnett
1,2
, Cheng-Han Ho
3
, Pin-Hsing Chou
3
, Fu-Chun Lee
3
, Li-Juan Ma
3
, Pei-Yu 
Lee
3
, Jian-Hau Chiou
3
, Yu-Chun Lin
3
, Yu-Han Shen
3
, Shih-Han Weng
3
, Adam Herrick
1
, 
Peter Nara
1,4
, Hsiao-Fen Grace Chang
3
, Hwa-Tang Thomas Wang
3
, Jessie Trujillo
1,5 
Iowa State University, Ames, Iowa College of Veterinary Medicine, Center for Advanced 
Host Defense Immunobiotics and Translational Comparative Medicine
1
, Departments of 
Veterinary Diagnostic and Production Animal Medicine
2
 and Veterinary Microbiology 
and Preventative Medicine
5
 
Biological Mimetics, Inc., Frederick, Maryland
4 
GeneReach USA, Lexington MA, USA
3
 
 
Abstract 
As diagnostic tools advance there is a growing number of rapid, effective, field 
diagnostic tools for the identification of pathogens. A 5 stage pipeline was determined for 
development and validation of field deployable devices. This present study utilizes 
pathogens related to Feline Upper Respiratory Disease including Feline Herpesvirus, 
Feline Calicivirus, Chlamydophila felis, Mycoplasma felis, and Bordetella 
bronchiseptica, and the candidate field deployable device, POCKIT™.  Validation, 
including limits of detection and exclusivity testing, of the pathogen specific Insulated 
Isothermal Polymerase Chain Reaction (iiPCR) as reagents on the field deployable device 
was performed against published reference assays. Thirty of both positive and negative 
clinical samples and surrogate samples were randomized, blinded, and tested side-by-side 
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on both platforms for each pathogen. Limits of detection were biologically relevant, were 
equal to or less than 10 infectious units, and demonstrated near equivalency with clinical 
samples for all pathogen targets. Exclusivity testing demonstrated the iiPCR to be 
pathogen and target specific. Sensitivity and specificity for clinical samples ranged from 
80%-97% and 93-100% respectively. Kappa values ranging from 0.80- 0.93 
demonstrated strong agreement. Results demonstrate exceptional performance of the 
iiPCR reagents for detection of feline respiratory pathogens in clinical samples. This 
study demonstrates the effectiveness of the iiPCR for detection of feline pathogens and 
the use of the stages 1 through 3 of the pipeline for validation of field deployable 
reagents. 
Introduction 
There is currently a drive for rapid, effective field diagnostic tools for the 
identification of pathogens. A five stage validation and translational pipeline for point of 
need diagnostics was developed and implemented for this purpose (Figure 1).  This 
systematic validation process is to ensure that point of need diagnostics are equivalent to 
current reference laboratory assays in sensitivity, specificity, exclusivity, and that results 
are reproducible in both laboratory and field settings. This streamlined validation system 
also allows for the rapid translation of assays to point of need field devices. The goal of 
this pipeline is to develop panels of assays that can be run in the field allowing for the 
early detection and triage of significant diseases. Once a target is detected, the sample 
would then be sent to a reference diagnostic laboratory for confirmation.  
71 
 
 
 
 
This study illustrates the five stage validation and translational pipeline through 
its application to Feline Upper Respiratory Disease Complex (FURD) pathogens as proof 
of concept with a candidate field deployable device. This disease complex is a leading 
cause of morbidity and mortality in cats, especially cats in group housing such as animal 
Figure 2.1. The Point of need reagent development, validation, and translational pipeline. 
This figure demonstrates the five general stages which can be applied to the rapid 
development and validation of a point of need reagents and their application in this 
specific study. 
 
shelters and catteries
6
. In a survey of 157 shelters in the Western United States, FURD 
was one of the top three diseases of concern reported by shelter workers
15
. FURD can be 
devastating in shelter environments as the pathogens spread quickly and cats enter 
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shelters with unknown vaccination and health statuses
6
. Additionally, cats in a stress 
inducing environments become immune compromised
6
.  While these factors can be 
affected through management practices such as isolation and vaccination of cats, the 
ability to properly diagnose and triage animals with FURD is essential to prevent the 
spread of disease, morbidity, and mortality.  
Pathogens that contribute to the development of disease and are targets for 
detection and identification include Feline Herpesvirus (FHV), Feline Calicivirus (FCV), 
Bordetella bronchiseptica (B. bronchiseptica), Chlamydophila felis (C. felis), and 
Mycoplasma felis (M. felis)
7,8,13,16,17.  Proper identification of the etiological agents’ 
specific to a FURD outbreak in a shelter environment allows for the targeted 
management and treatment. Currently pathogen detection is performed using molecular 
techniques at reference laboratories. The testing itself is expensive and shipping increases 
the time to results as well as the possibility of damage and loss of the samples. With the 
increase in veterinary involvement in shelters and the growth of shelter medicine, an in-
shelter point of need molecular detection system with equivalent sensitivity and 
specificity to reference assays would offer both a time and cost efficient means for early 
detection and triage of FURD for veterinarians while confirmatory testing occurs at 
reference laboratories.  
 The candidate device, POCKIT™ is small, stable, portable, and cost-efficient and 
could serve as a point of need device in the shelter environment for detection of FURD 
pathogens. This device uses lyophilized real-time compatible enzyme mixtures and 
oligonucleotides to perform Insulated Isothermal Polymerase Chain Reaction (iiPCR). 
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The iiPCR utilizes Rayleigh-Benard convection PCR
12
 in a capillary tube chamber
3
 with 
thermal baffeling
2
 in order to allow for PCR convection and amplification. The iiPCR 
system utilizes natural thermal convection within a capillary tube, caused by a stationary 
heat source maintained at a constant heat of 95
o
C, to drive fluid cycling
2
. The cycling of 
the reaction contents occurs through a temperature gradient that allows for denaturation, 
primer annealing, and elongation similar to qPCR. Completion of amplification of the 
nucleic acid occurs in under an hour. Initial proof of concept research has led to Office 
International des Epizooties (OIE) validation for detection of White Spot Syndrome 
Virus infection in Litopenaeus vannamei (shrimp)
26
.  
The objective of this study was to demonstrate the application of this validation 
pipeline for field deployable tests through the validation of the iiPCR for FURD 
pathogens. In this study, stages 1 through 3 of the validation pipeline were performed 
using the iiPCR Taqman reagents for the FURD pathogen targets FHV, FCV, Bordetella 
species (B. bronchiseptica, B. pertussis, and B. parapertussis), C. felis, and M. felis and 
reference laboratory assays. The data below provides evidence to demonstrate that the 
iiPCR is both sensitive and specific for the FURD targets and can serve as a point of need 
device for detection of pathogens relevant to shelter medicine and feline health.  
Materials and Methods 
Viruses and Bacteria 
M. felis strain 23391
a
 was reconstituted from lyophilized culture stocks in Friis 
Broth
b
, B. bronchiseptica strain 03127
a
 was reconstituted from lyophilized culture stocks 
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in BHI Broth
c
, FHV strain VR-636
a
, C. felis strain VR-120
a
, and FCV strain VR-530
a
 
were sourced from commercially available culture stocks. All pathogens were stored at -
80
o
C (Table 1).  
Colony forming units (CFU) were determined for M. felis and B. bronchiseptica 
reference strains through ten-fold serial dilutions spread in triplicate on Mycoplasma 
agar
d
 and Blood agar plates
e
 respectively. The plates were observed for growth and 
colony forming units were counted. The Mean Tissue Culture Infectious Dose (TCID50) 
for FHV and FCV, and Mean Chicken Embryo Infectious Dose (CEID50) for C. felis were 
sourced from the commercial product strain data sheet
e
 and extrapolated for DNA/RNA 
extraction and assay limits of detection.  
Nucleic Acid Extraction 
Manual nucleic acid extraction was performed using a commercial spin column 
extraction kit
g
. Procedures followed the kit protocol for non-nucleated blood, with the 
following modifications: 100µl of sample was used during lysis and incubated for 5 
minutes, during the final wash samples were centrifuged for 6 minutes at16,300 x g force, 
and nucleic acid was eluted into 100µl of the provided buffer preheated to 56
o
C. 
Extracted nucleic acid was stored at  -80
o
C. All extractions included pure target stock 
positive control and PCR-grade H20 negative control which were tested to confirm 
extraction success via qPCR.  
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Real-time PCR Reference Assays 
Table 1 includes the previously published primer and probe oligonucleotide 
sequences utilized for each assay, qPCR gene target, and positive control reference strain. 
All reference assays reported target gene accept for FHV and C. felis, for which the target 
genes were TK (GeneBank Accession FJ478159.2) and ompA (GeneBank Accession 
AP006861.1) respectively. M. felis qPCR
14
 was modified to included primers at 0.3µM 
concentration each, probe at 0.1µM concentration, and 4 µl of nucleic acid in a 24µl 
reaction. FHV and C. felis qPCR 
9
 was modified to single-plex 12.5µl reactions with 
primers and probes at 0.1uM concentration and 2.5µl of nucleic acid.  Bordetella species 
qPCR
10
 was modified to include primers at 0.2uM concentration each, probe at 0.1µM 
concentration, and 5µL of nucleic acid in a 25µl reaction. FCV qPCR
1
 utilized primers at 
0.3µM concentration, probe at 0.2µM concentration, and 5µL of nucleic acid in a 25µl 
reaction. All reactions utilized a commercially available qPCR mastermix
h
.  
Thermocycling was performed as described in references with the exception of 
the FCV assay where modifications included a cDNA synthesis step at 45
o
C for 10 
minutes followed by an initial denaturation step at 95
o
C for 1 minute and 45 PCR cycles 
of 95
o
C for 15 seconds, 56
o
C for 1 minute, and 72
o
C for 30 seconds. Each qPCR run 
included a well of the target control stock nucleic acid positive control and PCR-grade 
H2O negative control. Thermocycling was performed on a qPCR instrument
i
.  
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Internal Laboratory Validation of Selected Reference qPCR Assays 
Tenfold serial dilutions of extracted standard nucleic acid were prepared in PCR-
grade H2O for each reference strain and aliquots were made and frozen at -20
o
C. 
Dilutions of the standard nucleic acid were tested in triplicate in 3 scientific replicates for 
a total of 9 replicates.  Standard curves using the 9 replicates were generated for each 
assay. Standard curves were utilized to determine amplification efficiency and threshold 
cycle (Ct) for each assay. Once threshold limits were determined for each reference 
assay, all 187 clinical samples were run for each pathogen target in duplicate. Reference 
strain positive controls and PCR-grade H2O negative controls were included and analysis 
of runs were normalized. Samples with Cts below the threshold limit were considered 
‘positive’. Samples with no Ct were considered ‘not detected’. Samples with Cts above 
the threshold limit were considered ‘suspect’ and excluded from the study as they could 
not be classified as positive or not detected.  
Insulated Isothermal PCR Reagents 
Designed on the basis of the probe hydrolysis-based method described previously 
19
, the iiPCR reactions included primers and FAM-labeled hydrolysis probes specific for 
each target.  Nucleotide sequences available in the GenBank database were aligned to 
identify conserved regions to design target-specific primers and probes for the iiRT-PCR 
reagents.  For B. bronchiseptica detection, the Bordetella species iiPCR reagent was 
used. This reaction targeted the fimA gene and could detect three Bordetella species, 
namely B. bronchiseptica, B. pertussis, and B. parapertussis. 
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Table 3.1. The target pathogen, gene target, primer/probe oligonucleotide sequences
m
, and the reference control for each pathogen.  
Pathogen 
Target 
Gene 
Primer/Probe sets (5'→ 3') Region BP 
Positive 
Control
a
 
FHV
12
 TK 
Forward GGACAGCATAAAAGCGATTG 66291-6631 
75 VR-636 Reverse AACGTGAACAACGACGCAG 66365-66347 
CY5 Probe AATTCCAGCCCGGAGCCTCAAT  66319-66340 
FCV
1
 ORF1 
Forward GTAAAAGAAATTTGAGACAAT  1-21 
120 VR-530 Reverse TACTGAAGWTCGCGYCT  120-104 
FAM Probe CAAACTCTGAGCTTCGTGCTTAAA 26-49 
Bordetella 
species
13
 
FimA 
Forward ACTATACGTCGGGAAATCTGTTTG 838163-838140 
81 03127 Reverse CGTTGTCGGCTTTCGTCTG 838083-838101 
FAM Probe CGGGCCGATAGTCAGGGCGTAG  838134-838113 
C. felis
12
 ompA 
Forward GAACTGCAAGCAACACCACTG 1107246-1107266 
77 VR-120 Reverse CCATTCGGCATCTTGAAGATG 1107322-1107302 
FAM Probe CGCTGCCGACAGATCAAATTTTGCC  1107268-1107292 
M. felis
19
 tuf 
Forward TAAATTAGCTCTTGATGGTGTTCCT 469-493 
100 23391 
Reverse TTCAAAGTCTTTTTCTGGAGTTTCA 568-544 
HEX Probe 
TGAGAAGAAAAAGTTATGGAATTAA 
TGGATGCA 
497-529 
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Components of the iiPCR reaction, including dNTP, Taq DNA polymerase, 50 
mM Tris–HCl (pH 8.3), 75 mM KCl, 3 mM MgCl2, and 1 mM DTT, were lyophilized 
into two separate tubes, named Primer/Probe and dNTP/Enzyme, for each reagent. 
Primer/Probe was rehydrated with 50 µL of Reconstitution Buffer and the resulting 50 
µL mixture was then used to rehydrate dNTP/Enzyme. 5µL of the nucleic acid target or 
extracted sample was then added to this 50µL mixture and then 50µL of this total mixture 
was then transferred to the final reaction tube specific for this platform
j
.  The final 
reaction tube is then spun in a mini centrifuge
j
 for 10 seconds.  After which the final 
reaction tubes are placed into the reaction chamber of commercially available platform 
nucleic acid analyzer
j
 and the reaction program including reverse transcription and PCR 
was begun.  Readings of the 520-nm fluorescent signals generated from PCR 
amplification were collected and converted to “+” (positive) and “-“(negative) readouts 
by the system
26
. This plus minus detection system uses measurements of fluorescence 
before and after cycling to determine the ratio of fluorescence and a ratio of greater than 
1.5 is reported as a “+”. These results are then saved to a secure digital card in a 
commercially available data management program
k
.  
Limits of detection and exclusivity testing 
 LODs were determined in the following manner: the results from the original 
internal laboratory validation of the reference assays for each pathogen were analyzed 
and threshold cut off for the assays were determined to be the last dilution level at which 
all 100% of replicates had amplification above the Ct. Once this level was determined, 
two dilutions below and above this level as well as the cut-off dilution were run in 4 
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replicates iiPCR reagent replicates side-by-side with 3 qPCR reference assay replicates. 
100% LOD was determined for the iiPCR based on these 4 replicates and is defined as 
the last replicated to be 100% positive, although in many cases 75% and 50% detection 
occurred past the 100% LOD occurred.  
 Exclusivity testing was performed at the 10
4
 concentration of nucleic acid above 
the 100% reaction LOD for each iiPCR reagent and qPCR assay using FHV, FCV, B. 
bronchiseptica, C. felis, and M. felis nucleic acids. The M. felis iiPCR reagent was 
additionally tested with M. bovis strain 25025
a
, M. canis wild type strain, and M. arginini 
strain 27389
a
 nucleic acids. This testing was run side-by-side on the iiPCR and qPCR 
assays with 3 replicates for each pathogen.  
Absolute quantitation of DNA targets  
 Digital droplet PCR (ddPCR) was performed on the same set of standard 
reference nucleic acid as used for the LOD determination for the DNA targets FHV, 
Bordetella species, C. felis, and M. felis. Primers and probes used for the ddPCR were the 
same as those used for the qPCR assays. The ddPCR utilized a 25µL reaction comprised 
of: 12.5µL ddPCR Supermix
i
, 5µL of DNA target, the assay appropriate qPCR 
primer/probe concentrations, and PCR grade H2O to volume.  The generation of droplets 
and the reading of droplet number were performed per manufacturer instructions
11
. The 
ddPCR thermocycling conditions were the same as the qPCR assays.  
 Results from the ddPCR analyzer
i
 were recorded for absolute quantification of the 
number of DNA copies per 5µL DNA target for each dilution. These were then 
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extrapolated to template volume utilized in the qPCR and iiPCR reactions and reported as 
such. The ddPCR was not performed for FCV as it is an RNA target and there was 
difficulty with the RT step and this technology.  
Clinical samples and selection methods 
A total of 187 oro-pharyngeal clinical swabs collected from cats in shelters were 
available for this study. Of the 187 swabs collected, 69 were from cats exhibiting signs of 
FURD and 118 were from asymptomatic cats. For each pathogen target 30 known 
positive samples and 30 known negative samples were randomly selected (samples that 
had previously tested positive on the qPCR reference assays). The use of 30 positive and 
negative samples allowed for 5% error with 95% confidence when the analytical 
sensitivity and specificity were estimated at 98%. Figure 2.2 demonstrates the flow 
diagram used to create categories of swabs with various characteristics, from which the 
30 positive and negative samples were randomly selected.  Samples were divided into 
those from cats with and without FURD, those previously determined to be negative or 
positive for the assay specific pathogen, and based on the number of other pathogens 
detected in the sample. Random selection of samples was performed using a random 
number generator
k
.  All samples with suspect Cts or those whose repeat testing was 
inconsistent were omitted.  
All samples were run side-by-side on the iiPCR and reference assays. Samples 
were blinded by one author and the iiPCR and qPCR were run by two separate authors 
who did not know the blinded sample numbers. Results were reviewed after the runs for a 
specific assay were completed at which time the samples were un-blinded and 
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replacement samples were chosen when samples behaved as described above. In the case 
of the Bordetella species target four serial dilution replicates of stock B. bronchiseptica 
pathogen were utilized as positive samples as a limited number of positive clinical 
samples were available. C. felis only had one positive clinical sample, which was an 
ocular sample, so the positive samples were composed of randomly selected and blinded 
serial dilution replicates of stock pathogen. 
Statistical Analysis 
Measures of agreement were defined as analytical sensitivity, specificity, and 
Cohen’s kappa values for the purpose of evaluating the iiPCR reagents. Data were 
entered into an open source online generator
l
.  
Results 
Stage 1: Assay Selection 
 The first stage of the validation pipeline was completed with selected qPCR 
reference assays and developed iiPCR point of need reagents detecting the same gene 
targets for each pathogen(Table 3.1). The percentage of overlap in amplified nucleic acid 
sequences between the qPCR and iiPCR was 0% for FHV, 91.9% for FCV, 12.8% for 
Bordetella species, 78.6% for C. felis, and 73.6% for M. felis. 
Stage 2: Validation of qPCR Reference Assays 
 As the second stage of the validation pipeline, three scientific replicates resulting 
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Figure 2.2. Diagram of the clinical sample selection. This figure diagrams the selection of samples based on characteristics including 
whether the sample came from an animal with respiratory disease or not, whether the sample contained the target pathogen or not, and 
whether the sample was positive for other FURD pathogens and how many were present. 
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extracted standard nucleic acid. Table 3.2 and Figure 2.3 demonstrate the establishment 
of a standard curve for FHV through internal laboratory validation of LODs. Similar 
results were determined for the other target pathogens. The LODs determined for the 
reference assays were 10
0.1
 and 10
-1.10
 TCID50 for FHV and FCV respectively, 10
-0.03
 and 
10
-0.1
 CFU for B. bronchiseptica and M. felis respectively, and 10
-1.4
 CEID50 for C. felis. 
Table 3.2. Stage 2 reference assay validation demonstrated through establishment of 
Limits of Detection for Feline Herpesvirus using 9 replicates of stock standard pathogen.   
Target IFU* Ct Pos (n=9) 
FHV 
10^2.1 25.58 ± 0.46 9 
10^1.1 29.26 ± 0.62 9 
10^0.1 33.48 ± 0.78 9 
10^-0.9 36.76 ± 0.41 5 
10^-1.9 ND 0 
*IFU = Infectious units per reaction 
Figure 2.3. Feline Herpesvirus Standard Curve on the qPCR Laboratory Reference 
Assay. This graph demonstrates the standard curve for FHV pure culture control which 
was utilized to validate the reference laboratory qPCR assay. Standard curve was created 
via the running of a serial dilution set of the standard DNA in 9 replicates.  
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Stage 2: 100% Limits of Detection for Point of Need Reagents vs. Reference Assays 
 The 100% LODs were determined for the iiPCR reagents using 4 replicates run 
side-by-side with 3 replicates on the qPCR assays of 2 dilutions above and 2 dilutions 
below the previously determined qPCR LOD. The qPCR assays utilized 2.5µl of DNA in 
12.5µl reactions for FHV and C. felis, 5µl of DNA/RNA for B. bronchiseptica and FCV, 
and 4µl of DNA for M. felis. The iiPCR utilized 5µl of nucleic acid template in 50µl 
reaction for all targets. The results are displayed in Table 3.3.  The LODs were equivalent 
for FHV and FCV with both assays detected below 1 infectious unit. The qPCR was 1 log 
more sensitive than the iiPCR for B. bronchiseptica, C. felis, and M. felis. The iiPCR was 
able to detect 10
0.97
 CFU for B. bronchiseptica, 10
-0.3
 CEID50 for C. felis, and 10
1
 CFU 
for M. felis. 
 This shift in LOD shown in table 5 for the bacterial pathogens could be due to the 
percentage of nucleic acid in the assays, as the iiPCR uses approximately half the 
percentage of nucleic acid template that the qPCR uses, or could be due to variations in 
the DNA sequences amplified by the primer sets. To determine if this shift was due to the 
percentage of DNA in the reaction, the DNA in the iiPCR reactions for Bordetella 
species and M. felis was doubled (10µL DNA per 50µL reaction) so that there was 
equivalent input utilized and the dilution below the determined iiPCR LOD was rerun in 
triplicate. Normalizing for M. felis resolved discrepancy in LOD (100% LOD=10
0.3
), and 
normalizing for B. bronchiseptica only partially resolved the discrepancy in LOD (100% 
LOD=10
0.97
). The C. felis assay was not evaluated at this time due to the sensitivity of the 
assay and the biological relevance of its level of detection.  
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Table 3.3. LODs for comparison of the reference laboratory qPCR assays and the point of need iiPCR reagents utilizing serial 
dilutions of stock pathogens in side-by-side runs. iiPCR was performed using 5µl of nucleic acid in total 50µl reactions while qPCR 
was performed using 2.5µl per 12.5µl reaction for FHV and C. felis, 4µl per 25µl reaction for M. felis, and 5µl per 25µl reaction for B. 
bronchiseptica and FCV.  
Target 
qPCR iiPCR 
IFU* 
Genome 
equivalents† 
Ct 
Pos 
(n=3) 
IFU* 
Genome 
equivalents 
Fl ratio‡ 
Pos 
(n=4) 
FHV 
10^2.1 66.67 ± 2.36 24.97 ± 0.11 3 10^2.4 129.33 ± 4.73 4.07 ± 0.15 4 
10^1.1 4.21 ± 0.18 29.54 ± 0.14 3 10^1.4 8.42 ± 0.36 4.41 ± 0.15 4 
10^0.1 0.27 ± 0.05 33.00 ± 0.16 3 10^.4 0.54 ± 0.10 3.48 ± 0.63 4 
10^-0.9 0.01 ± 0.02 37.08 ± 0.74 2 10^-0.6 0.03 ± 0.05 3.51 ± 0 1 
10^-1.9 0.01 ± 0.03 ND 0 10^-1.6 0.03 ± 0.05 ND 0 
FCV 
10^.90 NP 30.68 ± 0.09 3 10^1.2 NP 5.00 ± 0.16 4 
10^-0.10 NP 35.20 ± 0.34 3 10^0.2 NP 4.99 ± 0.19 4 
10^-1.10 NP 37.20 ± 0.49 3 10^-0.8 NP 4.30 ± 1.08 4 
10^-2.10 NP 41.25 ± 1.29 2 10^-1.8 NP 1.44 ± 0.03 2 
10^-3.10 NP ND 0 10^-2.8 NP ND 0 
B. bronchiseptica 
10^1.97 20.23 ± 1.55 29.50 ± 0.36 3 10^1.97 20.23 ± 1.55 2.38 ± 0.54 4 
10^0.97 4.53 ± 0.84 33.38 ± 0.16 3 10^0.97 4.53 ± 0.84 2.48 ± 1.02 4 
10^-0.03 0.13 ± 0.04 37.35 ± 1.33 3 10^-0.03 0.13 ± 0.04 1.47 ± 0.23 2 
10^-1.03 0.03 ± 0.05 ND 0 10^-1.03 0.03 ± 0.05 ND 0 
10^-2.03 ND ND 0 10^-2.03 ND ND 0 
*IFU: Infectious units per reaction measured in TCID50 for FHV and FCV, CFU for B. bronchiseptica and M. felis, and CEID50 for 
C. felis. 
†Genome equivalents: Detected by absolute ddPCR for all DNA targets; NP = not performed.  
‡Fl ratio: Florescence ratio as determined by the internal computer of the POCKIT™ system is the ratio used to determine positive 
from negative samples, the average ratio and confidence interval were calculated using only positive wells; ND = not detected.  
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Table 3.3 Continued. 
Target 
qPCR iiPCR 
IFU* 
Genome 
equivalents† 
Ct 
Pos 
(n=3) 
IFU* 
Genome 
equivalents 
Fl ratio‡ 
Pos 
(n=4) 
C. felis 
10^0.4 59.17 ± 9.82 24.92 ± 0.06 3 10^0.7 
118.33 ± 
19.63 
3.58 ± 0.13 4 
10^-0.6 6.185 ± 0.48 29.04 ± 0.10 3 10^-0.3 12.37 ± 0.95 3.51 ± 0.27 4 
10^-1.4 0.685 ± 0.27 35.52 ± 0.19 3 10^-1.3 1.37 ± 0.55 1.98 ± 0.81 2 
10^-2.4 0.06 ± 0.05 36.03 ± 0 1 10^-2.3 0.12 ± 0.10 2.49 ± 0 1 
10^-3.4 0.14 ± 0.24 ND 0 10^-3.3 0.28 ± 0.48 ND 0 
M. felis 
10^1.9 8.91 ± 1.44 27.73 ± 0.03 3 10^2 11.14 ± 1.79 4.48 ± 0.16 4 
10^0.9 1.43 ± 0.17 31.64 ± 0.13 3 10^1 1.79 ± 0.21 3.55 ± 0.72 4 
10^-0.1 0.24 ± 0.16 35.11 ± 0.28 3 10^0 0.29 ± 0.20 1.33 ± 0 1 
10^-1.1 0.07 ± 0 ND 0 10^-1 0.08 ± 0 ND 0 
10^-2.1 ND ND 0 10^-2 ND ND 0 
 
 
 
 
 
8
6
 
 
87 
 
 
 
 
Stage 2: Exclusivity of Reference and Point of Need Reagents 
 Exclusivity testing was performed for both iiPCR and qPCR at 10
4
 concentration 
of nucleic acid above 100% reaction LOD for all specific target reagents resulted in no 
false positives. Table 3.4 demonstrates exclusivity results. Slightly expanded M. felis 
exclusivity was performed. No cross-reactivity was demonstrated for any pathogens. 
 
Table 3.4. Microbial exclusivity panel used for validation of the qPCR laboratory 
reference assay and the point of need iiPCR reagents for the target pathogens. 
Microbe 
Amplification with the specific qPCR and iiPCR reagents 
FHV FCV Bordetella species C. felis M. felis 
FHV +* - - - - 
FCV - + - - - 
B. bronchiseptica - - + - - 
C. felis - - - + - 
M. felis - - - - + 
M. bovis NP NP NP NP - 
M. canis NP NP NP NP - 
M. arginini NP NP NP NP - 
*+, positive amplification occurred; -, no amplification occurred 
NP=Not performed. 
 
Stage 3: Selection of Clinical Samples 
 Table 3.5 reports the characteristics that made up the clinical samples tested for 
each pathogen target. Clinical sample substitutions were made for both C. felis and 
Bordetella species due to a lack of positive clinical samples. For Bordetella species, 87% 
of pathogen positive samples were clinical samples while 13% were substituted serial 
dilution standards. C. felis had only 3% pathogen positive clinical samples and instead 
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utilized 97% substituted serial dilution standards. Overall, samples were broken into 4 
categories based on whether they were pathogen positive or negative and randomly 
selected from those categories to ensure a clinical sample population that reflected both 
multiple pathogen infections but also samples from cats with inflammation. 
Stage 3: Measures of Agreement Utilizing Clinical Sample Sets 
 For the stage 3 Analytical laboratory measures of agreement testing, 30 positive 
and negative samples were run for each target pathogen and analytical sensitivity, 
specificity, and kappa values were calculated. Measures of agreement performed were 
sensitivity and specificity and these are reported in Table 3.6. The sensitivity and 
specificity for FHV, FCV, Bordetella species, and M. felis were all 90% or greater and 
93% of greater respectively. The kappa values for these assays were also all 0.9 or 
greater.  C. felis had a sensitivity of 80% and a specificity of 100%. The kappa value for 
C. felis was 0.8. 
Discussion 
 This study illustrates the use of the 5 stage pipeline for validation of point of need 
field deployable devices. Validation of the laboratory reference qPCR assays and the 
iiPCR point of need reagents for FURD pathogens were used as proof of concept. This 
study demonstrates the effectiveness of this systematic approach to validation of a new 
point of need detection system and the development of reagents for those systems. Stage 
1 selection of laboratory qPCR reference assay and iiPCR primer and probe 
oligonucleotides resulted in detection of similar amplicon sequences for the pathogens 
FCV, C. felis, and M. felis and detection of different amplicon sequences for FHV and
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Table 3.5. Characteristic make-up of the clinical samples tested for each pathogen target including the number of samples that were 
positive and negative for the target, whether those samples were from cats that were positive or negative for FURD and if the samples 
tested positive or negative for other target pathogens (with percentages in parenthesis). 
Target 
Reagent 
Target positives (n=30)   Target negatives (n=30) 
FURD + 
 
FURD- 
Sub*  
FURD+ 
 
FURD- 
0 OP† 1+ OP   0 OP 1+ OP   0 OP 1+ OP   0 OP 1+ OP 
FHV 12 (40) 6 (20) 
 
9 (30) 3 (10) 0 (0) 
 
7 (23) 9 (30) 
 
7 (23) 7 (23) 
FCV 3 (10) 17 (57) 
 
5 (17) 5 (17) 0 (0) 
 
2 (7) 8 (27) 
 
6 (20) 14 (47) 
Bordetella sp. 3 (10) 12 (40) 
 
8 (27) 3 (10) 4 (13) 
 
7 (23) 9 (30) 
 
6 (20) 8 (27) 
C. felis 1 (3) 0 (0) 
 
0 (0) 0 (0) 29 (97) 
 
13 (43) 0 (0) 
 
9 (30) 8 (27) 
M. felis 6 (20) 9 (30)   6 (20) 9 (30) 0 (0)   5 (17) 11 (37)   7 (23) 7 (23) 
* Sub = Serial Dilution substitutes for samples without 30 positive clinical samples available 
†OP = Other pathogens present 
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Table 3.6. Measures of agreement between the qPCR laboratory reference assay and the point of need iiPCR reagent utilizing clinical 
samples, including the assay results for 30 positive and 30 negative blinded clinical samples, the sensitivity, specificity, and Cohen’s 
Kappa values (confidence intervals in parenthesis).  
Target Platform 
Assay Results   Measures of Agreement 
Positive 
(n=30) 
Negative 
(n=30) 
  Sensitivity Specificity Kappa 
FHV iiPCR 29 29 
  
96.7 (83.3,99.4) 96.7 (83.3,99.4) 0.93 (0.68-1.19) 
  
FCV iiPCR 29 28 
  
96.7 (83.3,99.4) 93.3 (78.7, 98.2) 0.90 (0.65-1.15) 
  
Bordetella 
species* 
iiPCR 27 30 
  
90.0 (74.4, 96.5) 100.0 (88.7, 100.0) 0.90 (0.65 - 1.15) 
  
C. felis* iiPCR 24 30 
  
80.0 (62.7, 90.5) 100.0 (88.7, 100.0) 0.80 (0.55 - 1.05) 
  
M. felis iiPCR 27 30  90.0 (74.4, 96.5) 100.0 (88.7, 100.0) 0.90 (0.65 - 1.15) 
  
*Bordetella species and C. felis testing utilized substituted serial dilution standards due to a lack of positive clinical    
  samples 
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Bordetella species. All assays and reagents targeted identical genes for each pathogen.  
 Stage 2 validation determined the LOD for pure-culture of each pathogen on both 
systems. Additionally, the LODs of the reference qPCR assay were demonstrated to be 
consistent and reproducible through 12 total replicates. The qPCR and iiPCR reactions 
were equivalent in LOD for both the FHV and FCV targets, with FHV detection at 1-2 
TCID50 or less than 0.5 genome equivalents; and FCV detection at 0.08-0.2 TCID50. This 
detection of FHV is 50 times less than the amount of FHV virus used in viral challenge 
models
18
 to induce infection.  Both the qPCR and iiPCR were determined to be equally 
sensitive for the detection of FHV and FCV.  The LOD for M. felis was equivalent when 
the amount of template nucleic acid was normalized between the qPCR and iiPCR and 
was then determined to be 0.8-2 CFU and this level of detection also falls below the 
experimental infectious dose
16
.  
The qPCR was one log more sensitive in LOD for both B. bronchiseptica and C. 
felis. The discrepancy in percentage of nucleic acid template added to reactions lead to 
possibly a biased result but equalizing the percentage of template did not change the LOD 
outcome for B. bronchiseptica as it did with M. felis. This may be due to B. 
bronchiseptica having a large, more complex genome which could be affected by the lack 
of denaturation stage on the iiPCR or the fact that there was only a 13% overlap in the 
amplified target sequence between the iiPCR and the qPCR. However this is unlikely to 
impact the ability of the assay to perform with clinical samples because its only one log 
shift in sensitivity and biological relevance the LODs for the iiPCR were still more 
sensitive than the concentration of B. bronchiseptica and C. felis previously determined 
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to cause disease through experimental inoculation
4,5
. The iiPCR reactions LODs were 
overall as sensitive as the qPCR reference assays and useful for the detection of 
biologically relevant levels of pathogen targets. Limited exclusivity testing and slightly 
expanded Mycoplasma species exclusivity was performed.  Exclusivity testing 
demonstrated that no cross-reactivity was present.  
Stage 3 testing determined the analytical measures of agreement for the iiPCR 
assay in relation to the qPCR reference assays through measures of sensitivity and 
specificity. The iiPCR was shown to be both sensitive (80% or greater) and specific 
(93.3% and greater) in relation to the qPCR reference assay for all pathogens. Kappa 
values for all reagents were above 0.8 and showed a high level of agreement between the 
qPCR and iiPCR reactions for the clinical samples. The C. felis reagent reported the 
lowest sensitivity (80%) and kappa value (0.8) but this assay also utilized surrogate serial 
dilutions of pathogen in the place of clinical samples as there was a lack of available 
positive clinical samples.  
Limitations of this study include the limited availability of feline pathogens for 
exclusivity testing. The M. felis qPCR assay had previously been tested for exclusivity 
against 17 Mycoplasma species and the FCV qPCR assay was previously tested for 
exclusivity against 7 feline pathogens but other assays did not have previous testing 
reported
1,14
. Further exclusivity testing will be performed before the beginning of stage 4 
and field trial validation. Another limitation of this study was the limited positive clinical 
samples for C. felis analytical testing.  It should also be noted that this study excluded 
‘suspect’ samples and only tested positive and negative samples with the intent of 
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obtaining analytical measures of agreement. The exclusion of ‘suspect’ samples in this 
study inserts spectrum bias, as when tested in the field, suspect samples would be 
expected to occur.  
While this study did have limitations, the experimental design was chosen in 
order to test each reagent with a wide array of clinical samples composed of both single 
and multiple pathogens. This was performed in order to test the reagent against clinical 
samples that best reflect those of the actual feline population. Both the qPCR and iiPCR 
were required to perform sensitive and specific detection in the face of multiple pathogen 
samples and samples with increased inflammatory debris and both reactions performed to 
high standards. Additionally, while there is no true ‘gold standard’ assay used in this 
study for comparison. The qPCR reference assays utilized went through vigorous internal 
validation and testing in order to establish an accepted standard of testing within the 
laboratory for the purpose of comparison and pathogen detection confirmation. This is 
one of the tenants of the field diagnostic validation pipeline.  
All of this testing must be utilized in conjunction with clinical symptomatology 
and appropriate confirmation from reference qPCR assays, but the ability to quickly 
determine sick animals pathogen burdens and appropriately isolate and triage diseases 
with high impacts on their populations, such as FCV is essential. With eight reactions per 
run, the commercial field-deployable system tested here is designed to fulfill the need of 
small-scale or satellite facilities. The iiPCR reagents could significantly lower the costs 
and shorten the sampling-to-result turn-around time from days to a few hours. 
Furthermore, sensitivity of the iiPCR reagents makes it possible to detect pathogens at 
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early stages, enabling users to take appropriate bio-security measures in a timely manner.  
These reagents can also facilitate on-site investigation of disease outbreaks, where 
relatively low numbers of known diseased animals are required to be tested.   The 
implementation of field deployable devices with the proper checks in place will not only 
save countless animals lives in shelter populations where disease spread is rapid and 
often fatal but also increase the overall health of our pet population, many of whom are 
adopted from these shelter environments. 
The 5 stage validation pipeline was implemented in this study to validate the 
iiPCR point of need reaction system for the detection FURD pathogens in feline samples. 
This study demonstrated that the iiPCR reagents are sensitive for the detection of 
biologically relevant levels of target pathogens in pure culture and in clinical sample 
screening. The iiPCR reactions were tested in a lyophilized format, which ensures 
stability of the reagents during the shipping and storage stages. Future validation of the 
iiPCR reagents through the application of stages 4, a field trial and development of 
standard operating procedures, and 5, the implementation of the iiPCR in shelter 
environments for detection of pathogens will be performed. This study demonstrated that 
the point of need validation pipeline can be utilized for the rapid development of point of 
need assays for significant pathogens and that the stringent testing and multi-step 
approach of the pipeline results in assays that are both sensitive and specific.  
Sources and Manufacturers 
a. Bacterial and viral reference strains, American Tissue Culture Collection, 
Manassas, VA.  
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b. Courtesy of Dr. Ricardo Rosenbusch, Iowa State University, Ames, IA 
c. BBL, Becton, Dickerson and Company, Sparks, MD 
d. Mycoplasma plates, California Davis 
e. Blood agar plates,  
f. Copan ESwab 480C and 481C, Copan Diagnostics Inc, CA  
g. DNeasy Blood & Tissue Kit and Quick-Start Protocol, QIAGEN, Valencia, CA 
h. Quanta Biosciences, Gaithersburg, MD 
i. Bio-Rad Laboratories, Hercules, CA 
j. GeneReach, Biotechnology Corporation, Taichung, Taiwan 
 
k. Microsoft Corporation, Redmond, WA 
l. OpenEpi, online 
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Abstract 
Background: Feline Upper Respiratory Disease is a disease complex that spreads rapidly 
through shelter housing environments and is a leading concern and cause of morbidity 
and mortality for felines in these environments.  
Objective: To assess detection of pathogens in ocular, nasal, and oro-pharyngeal samples 
from cats in a specific geographical region and evaluate their association with disease. 
Design: A cross-sectional study. 
Setting: Five animal shelters and a teaching hospital in the Iowa/Nebraska region from 
2011 to 2012. 
Cats: Cats with and without clinical signs of upper respiratory disease were sampled in 
shelters. Cats with disease were considered self-selected and cats without clinical signs 
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were then randomly selected through lottery and sampled. Cats recruited at the teaching 
hospital were self-selected by owners volunteering for participation.  
Measurements: Clinical signs were scored by severity by observers. Time in the shelter, 
age, and sex were also recorded for cats. Detection for pathogens (Feline Rhinotraceitis 
Virus (FHV), Feline Calicivirus (FCV), Chlamydophila felis (C. felis), Bordetella 
species, Mycoplasma felis (M. felis), the Mycoplasma gateae (M.gateae) cluster, and 
other Mycoplasma species) were performed utilizing Real-time Polymerase Chain 
Reaction diagnostic assays. Fischer’s exact testing, logistic regression, and backwards 
elimination models were performed.   
Results: 71 cats with respiratory disease and 119 cats without disease were enrolled in 
this study. Prevalence of FHV, FCV, C. felis, Bordetella species, M. felis, M. gateae 
cluster, and other Mycoplasma species in the total study population was 49%, 19.5%, 
3.2%, 23.7%, 40%, 24.7%, and 15.3% respectively. Multivariate modeling showed that 
detection of Bordetella species (odds ratio (OR) = 3.143), FCV (OR = 2.830), and 
housing cats in shelters for 2 to 6 months (OR = 0.146) were all significantly related to 
respiratory disease severity. Age of cats and detection of C. felis were confounding 
factors for relationship between Bordetella species and respiratory disease.   
Limitations: Intra-observer rating of clinical signs may have also resulted in changes in 
respiratory disease score. The decay of nucleic acids in samples and use of antibiotics in 
some of the cats may have limited pathogen detection.  
Conclusions: There risk factors associated with respiratory disease in this study were the 
detection of Bordetella species and the detection of FCV while being housed in the 
shelters for 2 to 6 months was a protective factor. 
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1. Introduction 
Feline Upper Respiratory Disease (FURD) is a complex disease characterized by, 
but not limited to, conjunctivitis, rhinitis, and tracheitis. Several etiological agents have 
been previously associated with the disease including Feline Rhinotracheitis Virus 
(FHV), Feline Calicivirus (FCV), Chlamydophila felis (C. felis), Bordatella 
bronchiseptica (B. bronchiseptica), and Mycoplasma felis (M. felis) (Tan, 1974; Hoover 
and Kahn, 1975; Gaskell and Povey, 1977; Sparkes et al., 1999; Speakman et al., 1999).  
FURD occurs commonly in group housed felines such as animal shelters 
(Dinnage et al., 2003). The level of confinement required in shelters and number of 
animals present can cause immunological stress. This can lead to high levels of morbidity 
and mortality associated with FURD (Dinnage et al., 2009). FURD was one of the top 
three diseases of concern identified by western US shelters in 2010 (Steneroden et al., 
2011) and was listed as one of the leading medical causes of feline death or euthanasia in 
shelters (Dinnage et al., 2009). There have been several studies in the past evaluating the 
association between FURD and various risk factors including pathogenic agents, age, 
breed, sex, and others (Bannasch and Foley, 2005; Helps et al., 2005; Hartmann et al., 
2010; Holst et al., 2010; Burns et al., 2011; Gourkow et al., 2013).  
Bannasch and Foley, 2005, evaluated 574 cats in California shelters and found 
that cats housed near dogs, cats in the shelter for less than 6 days and cats less than 12 
months of age were all at a higher risk of developing FURD. Helps et al., 2005, studied 
FURD in European catteries and found that the pathogens FHV, FCV, and B. 
bronchiseptica were all significantly associated with disease ad that the presence of dogs 
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and poor hygiene were risk factors. Hartmann et al., 2010, included 41 cats in Germany 
in an ocular study of FURD which found that there was a higher prevalence of 
Mycoplasma species detected than previously reported. Holst et al, 2010, utilized a case-
control methodology to sample the oro-pharynx and conjunctiva of 80 cats in Sweden 
and found that M. felis was associated with clinical signs of FURD. Burns et al., 2011 
evaluated close to 100 cats in a California shelter cats to determine that FHV was present 
in the majority of multiple pathogen infection. Gourkow et al., 2013, assessed 250 cats in 
a Canadian shelter and found that cats with FHV and B. bronchiseptica had the highest 
risk of developing FURD.  
None of these studies included samples from both the ocular, nasal and oral 
anatomical sites or took place in the upper Midwest. While studies utilizing Polymerase 
Chain Reactions (PCR) may have had similar sensitivities and specificities, studies 
utilizing culture and isolation methods would have markedly different sensitivity and 
specificities of the testing modalities. PCR is also more sensitive than culture methods for 
many of the FURD pathogens. Additionally, the studies either were case-control and 
included even number of healthy and diseased cats or only sampled from cats with 
FURD, making it difficult to assess the pathogen burden in the general shelter population.  
The objective of this study was to assess detection of pathogens in ocular, nasal, 
and oro-pharyngeal samples from cats in a specific geographical region and evaluate their 
association with disease using sensitive uniform methodology for pathogen detection and 
a large number of clinically normal cats.  
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2. Material and Methods 
2.1. Study Design 
This study utilized a cross-sectional design with populations of felines housed in 
animal shelters in the Iowa/Nebraska region of the Midwest and client-owned cats from 
the Lloyd Veterinary Medical Center (LVMC) at Iowa State University College of 
Veterinary Medicine. Felines in participating shelters were scored for clinical signs of 
FURD and sampled once. Felines seen at LVMC, whose owners consented to their 
participation, received the same scoring and sampling. Table 1 reports the demographics 
of the cats sampled. Conjunctival, oro-pharyngeal, and nasal swabs were collected from 
each participant. Sampling occurred from June 2011 to August 2012. Samples were 
tested for the presence pathogens (FHV, FCV, C. felis, Bordetella species, M. felis, M. 
gateae cluster, and other Mycoplasma species) via Real-Time Polymerase Chain 
Reactions (qPCR). Comparison of clinical FURD score, pathogen presence, time in the 
shelter, age, and sex were then statistically analyzed.  
2.2. Shelters and Clinic  
This cross-sectional study recruited the participation of animal shelters in the 
Iowa/Nebraska region and clients from the LVMC from June 2011 to July 2012. An 
enrolled shelter was visited several times during the study time period and at visit cats 
were enrolled in the study, scored, and sampled. Sampled occurred on the date of 
enrollment and no follow-up sampling was performed. Five animal shelters participated 
in this study and are referred to as A, B, C, D, and E. Shelters A and B were located in 
rural communities while shelters C, D, and E were located in urban communities. All 
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shelters were involved with animal control in either their city or county. All shelters 
housed both canines, felines, and assorted other domestic animal species. All shelters 
held stray cats for a minimum of 7 days before cats became shelter property.  
The Lloyd Veterinary Medical Center is located at Iowa State University College 
of Veterinary Medicine, in Ames, IA and provides clinical services to mostly client-
owned companion animals, exotics, and large animal species. If clients gave consent, cats 
were sampled while at appointment. Reasons for appointments included illness and 
preventative medicine.  
2.3. Feline participants 
Felines considered property of the participating shelters during the study time 
period were eligible to participate in the study and were only sampled once. Cats under 
the age of 8 weeks or less than 2 pounds in weight were excluded from this study. Shelter 
personal were asked to identify cats exhibiting clinical signs and symptoms of FURD in 
either their isolation or general populations. Cats that were safe to handle and exhibiting 
signs were considered self-selected for inclusion in the study. An effort was made to 
sample one cat without clinical signs for every cat with clinical signs. Healthy cats, cats 
without clinical signs of FURD, were randomly selected from the general population 
utilizing the Microsoft Excel Random Number Generator. Following best practices for 
disease prevention and biosecurity, all healthy animals and animals maintained in the 
general adoption population were sampled prior to those in isolation. In the shelters, 
isolation was considered any room that staff used to separate animals with clinical 
disease from the general adoption population. Felines presenting to the LVMC were 
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considered eligible to participate if owner consent was obtained at which point the feline 
was scored and sampled.  
The protocol for feline use was approved by the Institutional Animal Care and 
Use Committee (IACUC) of Iowa State University.  
2.4. Measures for outcomes and variables 
The outcomes of interest were FURD scores. FURD was determined using a 
clinical score card described below and the levels included: no clinical disease (0), mild 
disease (1), and severe disease (2). The variables of interest were the presence or absence 
of FHV, FCV, C. felis, 
Table 4.1. Demographic characteristics of the 190 sampled cats included in this study.  
Variable Classes Fraction Frequency (%) 
Shelter A 24/190 12.6 
B 46/190 24.2 
C 14/190 7.4 
D 47/190 24.7 
E 45/190 23.7 
LVMC 14/190 7.4 
Room in shelter Adoption 88/176 50 
Isolation 68/176 38.6 
Queening 4/176 2.3 
Other 16/176 9.1 
Time in shelter  
(days) 
≤ 30 78/141 55.3 
>30 and ≤60 33/141 23.4 
>60 and ≤180 28/141 19.9 
>180 2/141 1.4 
Sex Male 98/189 51.6 
Female 91/189 47.9 
Age  
(months) 
≤ 2 9/190 4.7 
>2 and ≤6  53/190 27.9 
>6 and ≤12 17/190 8.9 
>12 and ≤24 16/190 8.4 
>24  95/190 50 
Source Stray 16/43 37.2 
Owner surrender 27/43 62.8 
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Bordetella species, M. felis, M. gateae cluster, and other Mycoplasma species. Other 
variables and potential confounders included were: time spent in the shelter, age at time 
of sampling, and sex. Time in was measured in days. Age was measured in months. Sex 
was defined as male or female, regardless of whether the animal was intact or surgically 
altered.   
2.5. Data sources/measurements  
FURD scoring and the assays utilized for pathogen detection required 
measurements to be taken. All other variables were sourced from shelter records when 
available. Age was an estimate and was either reported on surrender or determined 
through dental exam.  
2.5.1. FURD Score Card and Scale 
At sampling cats were evaluated using a clinical score card by either a trained 
veterinarian or veterinary student. The overall general demeanor of the cat was noted as 
normal, depressed or severely depressed. Evaluators also noted the name/number of the 
cat and any distinct markings to avoid repeat sampling. Score cards also provided areas 
for other notes and comments on the cats such as any treatment being administered or 
clinical signs not related to upper respiratory disease but related to the general wellness of 
the cat. Characteristics evaluated were modeled from a previous study with modification 
(Bannasch and Foley, 2005). Conjunctivitis and keratitis were noted as either present or 
absent. Ocular and nasal discharge were marked as either normal (absent), clear (serous), 
or muco-purulent. Sneezing was normal (absent), occasional, or frequent/severe. 
Respiratory effort was evaluated as no effort, moderate effort, or dyspnea. Gingivitis, 
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plaque, and stomatitis/faucitis were evaluated on a scale of 0-3, 0 being normal (absent), 
1 being mild, 2 being moderate, and 3 being severe.  
A completed score card was used by the primary investigator to complete a total 
FURD score. This was assigned utilizing the “case definition and severity score” from a 
previous study with one modification (Bannasch and Foley, 2005). Based on this system, 
no clinical disease was noted if only mild serious ocular or nasal discharge or mild signs 
in one area were noted. Mild clinical disease was defined as score of 1 in several sites or 
the presence of purulent discharge in one site and mild serious ocular or nasal discharge 
with other clinical signs. Severe disease was all scores higher, including purulent 
discharge from the eyes and nose, severe signs in one location, and persistent sneezing 
during the examination. While the score cards were filled out by several individuals, the 
assignment of severity score was performed by a single individual to ensure consistency.  
2.5.2. Sample collection and qPCR for pathogen detection 
Samples in shelters were collected from each cat identified either as a FURD case 
or the randomly selected control. Individual conjunctival swabs were taken from both the 
right and left eyes when possible (Copan ESwab 481C, Copan Diagnostics Inc, CA). If 
nasal discharge was present, a third dry sterile nylon flocculated swab was rolled along 
the nasal planum. Finally, a deep oropharyngeal swab was taken (Copan ESwab 480C, 
Copan Diagnostics Inc, CA). All samples were kept cool and transported to the 
laboratory for processing as soon as possible. Samples collected in the teaching hospital 
were collected using the same material and methods but were then stored in refrigeration 
and were collected daily to be processed in the laboratory. Once in the laboratory all 
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samples were checked for proper labeling and then stored at -80
o
C. Nucleic Acid 
extraction was performed as described in a previous study (Donnett et al.,Chapter 4).  
2.5.3. qPCR assays for FHV, FCV, C. felis, Bordetella species, and M. felis 
The qPCR was performed for FHV, FCV, C. felis, Bordetella species, and M. felis 
using primers, probes, and thermocycling procedures previously described (Donnett et 
al., Chapter 4). For each target pathogen, a standard curve was created and the analytical 
sensitivity was determined. Samples were run in duplicate wells. The PCR positive 
control was specific to each assay were aliquots of the same, consistent, pure culture 
dilution of pathogen. Ct was standardized to the positive controls, thus normalizing 
fluorescence between separate runs (Thesis Chapter 4 Table 3.1) 
The standard curve for FHV demonstrated the assay to be sensitive up to 0.125 
TCID50 per reaction with an R
2
 of 0.998 and an amplification efficiency of 85.95%. The 
standard curve for FCV demonstrated the assay to be sensitive up to 0.07925 TCID50 per 
reaction with an R
2
 of 0.9718 and an amplification efficiency of 90.56%. The standard 
curve for C. felis demonstrated the assay to be sensitive up to 0.0025 CEID50/reaction 
with an R
2
 = 0.9976 and an amplification efficiency of 90.42%. The standard curve for 
Bordetella species demonstrated the assay to be sensitive up to the 9.4 CFU per reaction 
with an R2 of 0.9988 and an amplification efficiency of 87.60% . The standard curve for 
M. felis demonstrated the assay to be sensitive up to 1.2 CFU/reaction with an R
2 
= 
0.9969 and an amplification efficiency of 107.71%. Amplification efficiency was 
performed using an online calculator (Agilent Genomics, 
http://www.genomics.agilent.com/bioCalcs.jsp). 
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2.5.4. Pan-Myco SYBR qPCR for M. gateae cluster and other Mycoplasma species 
The M. gateae cluster and other Mycoplasma species were detected through the 
use of the Pan-Myco SYBR qPCR assay as previously described (Donnett et al., Chapter 
3). The standard curve for the M. gateae cluster demonstrated the assay to be sensitive up 
to 3 CFU per reaction with an R
2
 of 0.9957 and an amplification efficiency of 78.60%. 
This assay uses a single set of primers that bind to a conserved region of the Mycoplasma 
genome thus allowing for the amplification of any Mycoplasma species present in a 
sample (Donnett et al., Chapter 3). As such, the assay was tested for analytical sensitivity 
and specificity for representative Mycoplasma species.  
2.6. Bias 
While all personnel involved in sampling during this study were IACUC 
approved and instructed on sampling methods, throughout the course of the study there 
were three people involved in evaluation and scoring of animals for clinical signs and 
sample collection. This change in personnel could lead to classification bias in clinical 
signs thus affecting the outcome of the FURD score and detection bias if sampling 
methods were not identical across the samplers. There is also the possibility of selection 
bias as the cats selected as cases were identified by shelter personnel and may not have 
been exhibiting clinical signs at the time of sampling. This selection bias led to the 
uneven distribution of clinically ill and healthy cats (86 and 104 cats respectively).  
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2.7. Sample size 
The number of cats with FURD during the time period of this study in these 
shelters and their asymptomatic counterparts determined the number of cats in this study. 
Additionally, any cats from the LVMC that received client-consent were included.  
2.8. Quantitative variables 
For analysis, the variable ‘age’ was broken up into 5 categories. These categories 
were ≤ 2, >2 and ≤6, >6 and ≤12, >12 and ≤24, and >24 months. These categories were 
chosen for age breakdowns because they give an adequate assessment of the different 
stages of growth for a kitten and include age ranges that can be determined using dental 
scoring. Once a cat is older than 2 years and considered an adult it becomes difficult to 
determine its age, if for example it is a stray and has no past known history. For most of 
the respiratory pathogens, cats carry maternal immunity till around 2 months of age.  
The variable ‘time in’ days in the shelter was broken up into 4 categories. These 
categories were ≤ 30, >30 and ≤60, >60 and ≤180, and >180 days in the shelter. This 
break down was selected because it allowed assessment based roughly on the number of 
months spent in the shelter.  
2.9. Statistical Methods 
Statistical analysis was performed using the statistical software package SAS 
(SAS Institute Inc., Cary, NC). First descriptive analysis was performed for all of the 
variables for all of the FURD score levels (0,1,2). After descriptive analysis was 
performed, Fischer’s exact testing was performed. Fischer’s exact testing was used to 
evaluate the differences between models with the outcomes “FURD score 0,1,2”, “FURD 
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score 0-1, 2”, and “FURD score 0, 1-2”. It was determined that the outcomes 1 (mild 
disease) and 2 (severe disease) could be combined, and further modeling was performed 
using the outcome “FURD score 0, 1-2”.  
Modeling was first performed using the outcomes any pathogen detection and 
multiple pathogen detection. Any pathogen detection was a dichotomous variable while 
multiple pathogen detection was treated as a categorical variable with the classes 
reflecting the number of pathogens detected overall in a cat, ie. 0-1, 2,3,4,5. First 
univariate modeling, maximum likelihood point estimate analysis of each variable, and 
the odds ratio and 95% confidence interval were determined for these variables. Than an 
multivariate model adjusting for age, time in, and sex was analyzed. 
Next univariate models were run for all the individual variables. The variables 
Sex, FHV, FCV, C. felis, Bordetella sp., M. felis, M. gateae cluster, and other 
Mycoplasma were all analyzed through logistic regression as dichotomous variables. The 
variables Age and Time in shelter were analyzed through logistic regression as 
categorical variables as described above. Each variable was first analyzed using a 
univariate linear logistic regression model with “FURD score 0, 1-2” as the outcome and 
the variable in question as the explanatory variable for using a maximum likelihood 
method of estimation. As a single sample was taken from each subject an adjusted 
multivariate model was deemed to be appropriate.  
Following univariate modeling, maximum likelihood point estimate analysis of 
each variable, and determination of the odds ratio and 95% confidence interval, an 
adjusted multivariate model including all variables as the explanatory variables and 
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“FURD Score 0,1-2” as the outcome was analyzed. In the multivariate model Sex, FHV, 
FCV, C. felis, Bordetella sp., M. felis, M. gateae cluster, and other Mycoplasma were 
included as dichotomous variables and Age and Time in shelter were included as grouped 
categorical variables. All cats with missing data values were excluded from multivariate 
analysis and the working feline sample number for this modeling was 141 cats.  
The initial model for logistic regression formulated above had “FURD score 0, 1-
2” as the outcome variable and included all possible main effects (sex, age, time in the 
shelter, FHV, FCV, C. felis, Bordetella sp., M. felis, M. gateae cluster, and other 
Mycoplasma). The model was then simplified using hierarchical backwards elimination. 
This procedure was run and the result was considered the unadjusted final model. 
Predictors with the largest p-value above 0.05 were removed from the model one at a 
time and assessed for confounding. A variable was considered to be a confounder if its 
inclusion in the multivariate model altered the OR for the association between “FURD 
score 0, 1-2” and Bordetella sp. by 10% or more. If the variable was found to be a 
confounder it was retained in the model. Backwards elimination was continued until all 
variables in the model had either a significant p-value of equal to or less than 0.05, or 
were found to be confounders. This was determined to be the final adjusted model. This 
final adjusted model was then used to find the maximum likelihood point estimate 
analysis for each variable and the odds ratio and 95% confidence intervals were also 
determined. The p-value was considered significant at <0.05. 
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3. Results 
3.1. Feline demographics 
5 shelters and 14 clients at the LVMC consented to participation in this study. A 
total of 190 cats were samples for this study including: 24 (12.6%) from shelter A, 46 
(24.2%) from shelter B, 14 (7.4%) from shelter C, 47 (24.7%) from shelter D, 45 (23.7%) 
from shelter E, and 14 (7.4%) from the LVMC. The wide range in numbers of cats 
sampled at shelters was dependent upon the cat population in the shelters and the number 
of times the shelter was visited for sampling. Shelters farther than 60 minutes from Ames, 
IA were sampled at a single visit.   The demographic breakdown of feline participants 
included in this study is displayed in Table 1. Of the 190 cats, 176 were members of 
shelter populations. Of these 176 cats, 141 had data available and collected on their 
length of time spent in the shelter and 43 had data available and collected on their source 
prior to shelter housing. One shelter cat had missing data related to sex. The majority of 
shelter cats in this study were housed in the general adoption population (50%) with the 
isolation housing being the second largest population (38.6%). The large majority of 
shelter cats sampled were also owner surrenders (62.8%). More than half of the shelter 
cats (55.3%) had been in the shelter for 30 days or less. The overall cat population was 
equally distributed between male (51.6%) and female (47.9%). The majority of cats were 
either between the age of 2 and 6 months (27.9%) or older than 24 months (50%).  
All 190 participating cats were clinically scored for FURD. Table 4.2 
demonstrates the number of cats with specific clinical signs and their assigned overall 
FURD severity score. The most prevalent clinical signs observed in cats were serous 
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ocular discharge (24.2%), sneezing (25.8%), gingivitis (21.1%), and a body condition 
score of less than 3 on a scale of 1-5 (16.3%). While all these clinical signs can be caused 
by factors other than FURD, the combination of multiple of these in an individual was 
considered clinical signs of disease. Cats which appeared most severely affected by upper 
respiratory disease had higher prevalence of serous ocular discharge (11.1%), sneezing 
(17.4%), and stomatitis (5.3%) than cats with no or mild disease scores. The majority of 
cats with low body condition scores did not have clinical signs of disease (11.6%).  
Table 4.2. The number (and percentage) of cats with specific clinical signs and the 
overall assigned FURD severity score.  
Clinical signs FURD Severity Score Total 
0 (none) 1 (mild) 2 (severe) 
Conjunctivitis 2 (1.1) 7 (3.7) 9 (4.7) 18 (9.5) 
Keratitis 0 (0) 2 (1.1) 3 (1.6) 5 (2.6) 
Serous ocular discharge 13 (6.8) 12 (6.3) 21 (11.1) 46 (24.2) 
Purulent ocular discharge 0 (0) 2 (1.1) 6 (3.2) 8 (4.2) 
Serous nasal discharge 2 (1.1) 5 (2.6) 12 (6.3) 19 (10) 
Purulent nasal discharge 0 (0) 4 (2.1) 11 (5.8) 15 (7.9) 
Sneezing 7 (3.7) 9 (4.7) 33 (17.4) 49 (25.8) 
Gingivitis 12 (6.3) 15 (7.9) 13 (6.8) 40 (21.1) 
Stomatitis/Faucitis 0 (0) 3 (1.6) 10 (5.3) 13 (6.8) 
Body condition score < 3 22 (11.6) 3 (1.6) 6 (3.2) 31 (16.3) 
Total cats 119 (62.6) 32 (16.8) 39 (20.5) 190 
 
3.2. Total FURD score and pathogen detection 
Of the 190 cats sampled in this study, 119 (62.6%) had a clinical FURD score of 0 
or no disease. Cats with disease broke down into 32 (16.8%) cats with a FURD score of 
1, or mild, and 39 cats with a FURD score of 2 (20.5%), or severe. Table 4.3 provides a 
breakdown of FURD score and pathogen detection per housing location. With the 
exception of Shelter C, all shelters had animals sampled that received scores of 0, 1, and 
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2 for FURD. The majority of the cats sampled in shelters, 111 (63.1%) had no clinical 
disease.  
Table 4.3. Total numbers of cats with each FURD severity score per housing location as 
well as the prevalence (percent) of detected pathogens in the 5 animal shelters and the 
LVMC cats.  
 Housing location All 
shelters LVMC A B C D E 
Cats sampled 14 24 46 14 47 45 176 
FURD 
Severity 
Score 
0 (none) 
8  
(57.1) 
19  
(79.2) 
26  
(56.5) 
11  
(78.5) 
32  
(68.1) 
23  
(51.1) 
111 
(63.1) 
1 (mild) 
2  
(14.3) 
3  
(12.5) 
7  
(15.2) 
3  
(21.4) 
5  
(10.6) 
12  
(26.7) 
30  
(17.1) 
2 (severe) 
4  
(28.6) 
2  
(8.3) 
13  
(28.3) 
0  
(0) 
10 
(21.3) 
10  
(22.2) 
35  
(19.9) 
Pathogens 
detected 
FHV 
2  
(14.3) 
8  
(33) 
33  
(71.7) 
1  
(7.2) 
34  
(72.3) 
15  
(33.3) 
91  
(51.7) 
FCV 
1  
(7.1) 
3  
(12.5) 
12  
(26.1) 
1  
(7.2) 
16  
(34) 
4  
(8.9) 
38  
(21.6) 
C.felis 
4  
(28.6) 
0  
(0) 
1  
(2.2) 
0  
(0) 
1  
(2.1) 
0  
(0) 
2  
(1.1) 
Bordetella 
sp.  
1  
(7.1) 
3  
(12.5) 
23  
(50) 
1  
(7.2) 
0  
(0) 
17  
(37.8) 
44  
(25) 
M. felis 
4  
(28.6) 
8  
(33) 
16  
(35) 
6   
(42.9) 
16  
(34) 
26  
(57.8) 
72  
(40.9) 
M. gateae 
cluster 
8  
(57.1) 
7  
(29) 
11 
(22.4) 
5  
(35.7) 
11  
(23.4) 
5  
(11.1) 
39  
(22.2) 
Other 
Mycoplasma 
sp.  
7  
(50) 
3  
(12.5) 
8  
(17.4) 
1  
(7.2) 
6  
(12.8) 
4  
(8.9) 
22  
(12.5) 
 
FHV was detected in 91 (51.7%) of the shelter cats with shelters B and D having 
the highest prevalence of FHV detection at 71-72%. FCV was detected in 38 (21.6%) of 
the cats with the highest prevalence of detection in shelter D (34%). C. felis was only 
detected in 2 (1.1%) shelter cats, 1 cat from shelter B and one cat from shelter D. The 
majority of the C. felis detection occurred in home-owned cats at the LVMC (28.6%). 
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Bordetella species were detected in 44 (25%) of the shelter cats with the highest 
prevalence being in shelter B (50%). Only 1 (7.1%) home-owned cat had Bordetella 
species detected. M. felis had the second highest prevalence of the pathogens detected, 
being found in 72 cats (40.9%). The majority of these detections (36.1%) occurred in cats 
from shelter E.  
M. gateae cluster was detected in 39 (22.2%) of cats in shelters and other 
Mycoplasma species were detected in 22 (12.5%) of cats in the shelters. The other 
Mycoplasma species detected included M. canis, M. hyorhinis, M. alkalescens, M. cynos, 
M. faucium, M. dispar, M. buccale, M. spumans, M. hominis, M. bovis, M. bovoculi, M. 
maculosum/leopharyngis cluster, and 2 new unknown species and more information can 
be found in the previous publication detailing detection and differentiation of these 
species (Donnett et al., Chapter 3).  
The results for the modeling of FURD score severity against pathogen detection 
can be found in Table 4.4. In the unadjusted odds rate model which includes the data 
from 190 cats, the odds of having mild to severe FURD if any pathogen was detected was 
4.34 (0.98, 19.29) times that of cats with no pathogens detected. This odds ratio has a 
wide confidence interval and includes the null and the p value (0.054) is just above the 
significant level of 0.05 but is significant at a level of 0.10. Overall, this provides weak 
evidence that the detection of any pathogen increases the odds of FURD. Modeling 
adjusting for age, time in the shelter, and sex of the cats resulted in 3.99 (0.869, 18.336) 
odds of having mild to severe FURD if any pathogen was detected. Again the p value of 
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0.0752 is only significant at the 0.1 level and the null is included in the 95% confidence 
interval.  
In the unadjusted odds rate model the odds of having mild to severe FURD if 
multiple pathogens are detected was only significant for the detection of 4 pathogens in a 
single cat. The odds of having mild to severe FURD if 4 pathogens were detected was 
6.44 (1.524, 27.246) times that of cats with 0 or 1 pathogen detected. The p value for the 
detection of 4 pathogens in a single cat was 0.0299, although the confidence interval for 4 
pathogens detected was very wide, which suggests that this is imprecise. When the model 
was adjusted for the variables age, time in the shelter, and sex of the cats, no level of 
multiple pathogen detection was found to be significantly related to FURD.  
Table 4.4. Relative rates of any pathogen and multiple pathogens detection and the 
measures of association with any pathogen detected and multiple pathogens detected.  
  Unadjusted Odds Rate Adjusted Odds Rate 
  
Odds 
ratio 
95% 
CI 
P 
Odds  
ratio 
95% 
CI 
P 
Any 
pathogen 
0  Ref - - Ref - - 
1+ 4.34 (0.98, 19.29) 0.054 3.99 (0.87, 18.34) 
0.07
52 
Multiple 
pathogens 
detected 
0-1 Ref - - Ref - - 
2 2.53 (1.27, 5.03) 0.2635 3.340 (1.42, 7.88) 
0.91
86 
3 1.38 (0.54, 3.55) 0.5947 9.469 (0.84, 9.47) 
0.92
16 
4 6.44 (1.52, 27.25) 0.0299 3.812 (0.71, 20.57) 
0.91
62 
5 0.69 (0.07, 6.53) 0.3131 -0.001 
(<0.001, 
>999.9) 
0.92
41 
Adjusted odds rate for age, time in the shelter, and sex of the cats 
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3.3 Univariate and multivariate modeling for FURD scores and all factors 
The results from the univariate modeling for all possible main effects are 
displayed in Table 4.5. Age greater than 24 months, >60 days in the shelter to ≤180 days 
in the shelter , and Bordetella species detection were all associated with the outcome 
FURD score of mild or severe at the 0.05 significance level. None of these variables had 
confidence intervals that included the null. The odds of having mild or severe FURD for 
a cat over 24 months of age was 0.126 (0.025, 0.642) times that of a cat less than or equal 
to 2 months of age and had a p value of 0.0133.  The odds of having mild or severe 
FURD for a cat in a shelter for greater than 60 days and less than or equal to 180 days 
was 0.281 (0.097, 0.817) times that of a cat in the shelter for less than or equal to 30 days 
and had a p value of 0.0415. The odds of having mild or severe FURD for a cat with 
Bordetella species detected was 2.113 (1.071, 4.167) times that of a cat without 
Bordetella species and had a p value of 0.0309. FCV was also associated with the 
outcome FURD score of mild or severe at the 0.1 significance level. The odds of having 
mild or severe FURD for a cat with FCV detected was 2.050 (0.992, 4.239) times that of 
a cat without FCV and had a p value of 0.0527. Overall, when modelled independently, 
cats older than 24 months of age and cats in the shelter for 3 to 6 months had decreased 
risk of mild or severe FURD while cats with Bordetella species detected and cats with 
FCV detected were at increased risk of mild or severe FURD.  
The results of the multivariate backwards elimination modeling are reported in 
Table 4.6. The variables C.felis, other Mycoplasma species, M. felis, Age, FHV, sex, and 
M. gateae cluster were removed from the model via backwards elimination in that order. 
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Once removed, assessment for confounding found that the variables C. felis and age 
significantly increased the OR for Bordetella species by more than 10%. Therefore they 
were replaced in the model and were considered confounding factors. The variables 
Bordetella species, FCV, and time in the shelter all had statistical significance and so 
remained in the model. The final unadjusted model included the exposure variable of 
interest Bordetella species and the modifying factors FCV and time in the shelter. There 
were no confounding factors in the unadjusted model. The final adjusted model included 
the exposure variable of interest Bordetella species and the modifying factors FCV, time 
in the shelter, age, and C. felis. This model included the confounding factors age and C. 
felis. 
In the unadjusted model, the odds of having mild or severe FURD for a cat with 
Bordetella species detected was 2.529 (1.01, 6.35) times that of a cat without Bordetella 
species and had a p value of 0.0481. The odds for a cat with FCV detected was 3.380 
(1.30, 8.83) times that of a cat without FCV and had a p value of 0.0129. The odds for a 
cat in a shelter for greater than 60 days and less than or equal to 180 days was 0.165 
(0.05, 0.54) times that of a cat in the shelter for less than or equal to 30 days and had a p 
value of 0.0367. In the adjusted model, the odds of having mild or severe FURD for a cat 
with Bordetella species detected was 3.143 (1.19, 8.32) times that of a cat without 
Bordetella species and had a p value of 0.0211. The odds for a cat with FCV detected 
was 2.830 (1.07, 7.49) times that of a cat without FCV and had a p value of 0.0363. The 
odds for a cat in a shelter for greater than 60 days and less than or equal to 180 days was. 
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Table 4.5. Descriptive analysis and univariate point estimates, p-values, and odds ratios for FURD prevalence with risk factors. 
Variable Category 
FURD Prevalence Odds Ratio 95% Confidence 
Interval 
P value 
0 1-2 
Age (months) ≤ 2 2 (1.1) 7 (3.7) Referent - -  
>2 and ≤6  32 (16.8) 21 (11.1) 0.188 (0.35, 0.991) 0.3358  
>6 and ≤12 10 (5.3) 7 (3.7) 0.20 (0.032, 1.265) 0.5931  
>12 and ≤24 9 (4.7) 7 (3.7) 0.222 (0.035, 1.422) 0.7705  
>24  66 (34.7) 29 (15.3) 0.126 (0.025, 0.642) 0.0133 ** 
Sex Male 57 (30.2) 41 (21.7) Referent - -  
Female 61 (32.3) 30 (15.9) 0.684 (0.378, 1.238) 0.2092  
Time In Shelter 
(days) 
≤ 30 44 (31.2) 34 (24.1) Referent - -  
>30 and ≤60 17 (12.1) 16 (11.3) 1.218 (0.538, 2.755) 0.3841  
>60 and ≤180 23 (16.3) 5 (3.5) 0.281 (0.097, 0.817) 0.0415 ** 
>180 1 (0.7) 1 (0.7) 1.294 (0.078, 21.446) 0.6673  
FHV Negative 65 (34.2) 32 (16.8) Referent - -  
Positive 54 (28.4) 39 (20.5) 1.467 (0.813, 2.648) 0.2034  
FCV Negative 101 (53.2) 52 (27.4) Referent - -  
Positive 1 (9.5) 19 (10.0) 2.050 (0.992, 4.239) 0.0527 * 
C. felis Negative 115 (60.5) 69 (36.3) Referent - -  
Positive 4 (2.1) 2 (1.1) 0.833 (0.149, 4.670) 0.8357  
Bordetella sp. Negative 97 (51.1) 48 (25.3) Referent - -  
Positive 22 (11.6) 23 (12.1) 2.113 (1.071, 4.167) 0.0309 ** 
M. felis Negative 72 (37.9) 42 (22.1) Referent - -  
Positive 47 (24.7) 29 (15.3) 1.058 (0.581, 1.926) 0.8541  
M. gateae cluster Negative 90 (47.4) 53 (27.9) Referent - -  
Positive 29 (15.3) 18 (9.5) 1.054 (0.535, 2.079) 0.8789  
Other 
Mycoplasma sp. 
Negative 100 (52.6) 61 (32.1) Referent - -  
Positive 19 (10.0) 10 (5.3) 0.863 (0.376,1.977) 0.7273  
Significance levels reported: *=0.1 significance; **=0.05 significance; ***=0.005 significance 
 
1
1
9
 
 
120 
 
 
 
 
 
 
 
 
Table 4.6. Multivariate point estimates, p-values, and odds ratios for Bordetella sp. related to FURD prevalence with both the 
unadjusted odds rate and adjusted odds rate for confounding variables.  
Variables Category 
FURD Score Unadjusted Odds Rate Adjusted Odds Rate 
0 1-2 
Point  
estimate 
95% 
CI 
P 
Point  
estimate 
95% 
CI 
P 
Bordetella 
sp. 
Negative 97 (51.1) 48 (25.3) Referent - - Referent - - 
Positive 22 (11.6) 23 (12.1) 2.529 (1.01, 6.35) 0.0481 3.143 (1.19, 8.32) 0.0211 
FCV 
Negative 101 (53.2) 52 (27.4) Referent - - Referent - - 
Positive 1 (9.5) 19 (10.0) 3.380 (1.30, 8.83) 0.0129 2.830 (1.07, 7.49) 0.0363 
Time in 
shelter 
≤ 30 44 (31.2) 34 (24.1) Referent - - Referent - - 
>30 and 
≤60 
17 (12.1) 16 (11.3) 0.919 (0.38, 2.25) 0.3158 0.780 (0.31, 1.97) 0.4903 
>60 and 
≤180 
23 (16.3) 5 (3.5) 0.165 (0.05, 0.54) 0.0367 0.146 (0.04, 0.50) 0.0258 
>180 1 (0.7) 1 (0.7) 0.593 (0.02, 15.35) 0.9485 0.761 (0.03, 20.46) 0.7865 
Adjusted odds rate for confounding variable age and C. felis.  
 
 
 
 
1
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0.146 (0.04, 0.50) times that of a cat in the shelter for less than or equal to 30 days and 
had a p value of 0.0258. 
4.0     Discussion 
This study was an evaluation of FURD in shelter cats and its potential risk factors 
in a unique geographical location. The sample population was composed of 190 cats from 
5 participating shelters and one hospital. Of these cats, 119 (62.6%) had no clinical, 32 
(16.8%) cats had a mild FURD, and 39 (20.5%) cats with severe FURD. Cats ranged in 
age from 2 months to 15 years of age. The study population was equally divided between 
male and female cats and ranged in time housed in the shelter from 0 days to 285 days. 
The majority of cats included in the study were owner surrenders (62.8%). FHV was the 
pathogen most commonly detected in the sampled cats at 51.7% with M. felis being the 
second most common pathogen (40.9%) and Bordetella species, FCV, and M. gateae 
cluster (21-25%) all being the third most commonly detected. 
Individually significant variables included age, time in shelter, FCV, and 
Bordetella sp. The odds of FURD in cats greater than 24 months of age was 0.126 (0.025, 
0.642) with a p value of 0.0133 suggesting older cats are at a decreased odds of FURD as 
compared to cats 2 months of age or younger. Cats in the shelter for 2-6 months also had 
significantly decreased odds of FURD. Cats with Bordetella species detected and cats 
with FCV detected had increased odds of FURD. 
Multivariate modeling utilized FURD as the outcome of interest and suggested 
that the detection of the pathogens Bordetella species and FCV are related risk factors. 
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Additionally, being housing in the shelter greater than 60 days and less than or equal to 
180 days also appeared to be a related protective factor. When all significant factors were 
included in the fully adjusted model, the odds of FURD in a cat positive for Bordetella 
species was 3.143 (1.19, 8.32) times that of a negative cat. Overall, the detection of 
Bordetella species and FCV appeared to increase a cat’s odds of FURD and being housed 
in the shelter for greater than 60 days and less than or equal to 180 days decreased the 
risk of FURD. The age of a cat and the detection status of C. felis were also found to 
confound the relationship between Bordetella species and the risk of FURD. 
There were several limitations to this study.  The rare detection of the pathogens 
C. felis and other Mycoplasma species in this population of cats and as such their 
detection was not significant. The inability to find all the variable information on shelter 
paperwork resulted in only 141 of the 176 shelter cats having a reported time in the 
shelter. While this limited the number of cats included in multivariate analysis, this also 
exclude the client owned cats from this analysis. There was limited data available and 
collected on treatments cats had received that may have affected detection of pathogens. 
Shelter protocols varied in treatment methods with common antimicrobials used 
including oral clindamycin, potentiated amoxicillin, oxytetracycline ointment, and oral 
doxycycline. The majority of these drugs have limited efficacy against both C. felis and 
M. felis but are effective against Bordetella species (Sparkes et al., 1999; Hartmann et al., 
2008; Ruch-Gallie et al., 2008; Litster et al., 2012). Appropriate antimicrobial treatment 
could decrease the pathogen load before clinical signs abate and reduce the detection of 
bacterial pathogens. This did not lead to bias in the detection of viral pathogens.  
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Due to the nature of this cross-sectional study and the limited data available on 
the length of clinical signs prior to testing, cats were likely sampled during all stages of 
illness, recovery, and health. This sampling also affected the pathogen load, shedding, 
and detection. Additionally,  animals were often maintained in isolation for a period after 
clinical signs have abated to ensure their health and protect the healthy adoption 
population, so these animals, while originally isolated for FURD signs, were also scored 
as asymptomatic at the time of sampling. It was also noted during this research that pure 
culture Bordetella bronchiseptica had significant denaturation during freeze thaw cycles 
and holding in refrigeration. This may have resulted in marked underestimates of 
Bordetella species prevalence in this cat population.  
Conversely, this study utilized a population of cats in a unique geographical area 
and sampled from a large number of clinical healthy cats. The use of the large number of 
clinically healthy cats increases the power of pathogen association with disease. The 
results of this study suggest that the pathogens Bordetella species and FCV are important 
to the severity and demonstration of clinical signs of respiratory disease in cats and 
increase these signs. Older animals and cats housed in the shelter environment for 2-6 
months have decreased disease severity. Overall, Bordetella species detection increased 
the odds of disease in cats by 3 times. All of these shelters also housed dogs and this may 
contribute to the presence of Bordetella species in the environment and possible 
transmission to the cat population.  
It has been shown previously that cats housed in facilities with dogs have 
increased risk of developing FURD (Binns et al., 1999; Helps et al., 2005). Several 
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previous studies have demonstrated that younger cats have an increased risk of disease 
(Dinnage et al., 2003; Bannasch and Foley, 2005; Wong et al., 2013). This study also 
found that older cats have decreased odds of FURD which agrees with previous findings. 
This is likely due to these animals having been previously vaccinated or exposed to the 
pathogens and recovered. Additionally, older animals may be animals that have been 
housed in the shelter environment. Age was also found to be a confounder of the 
relationship between Bordetella species detection and FURD. This suggests that age may 
have an impact on whether a cat has Bordetella species present and detectable. In this 
study time in the shelter was also found to significantly affect the odds of a cat having 
FURD. Cats housed in the shelter for 2-6 months had a decreased risk of developing 
FURD in relation to those cats housed in the shelter for 1 month or less. One previous 
study suggested that exposure and disease occurred early in shelter stay for cats, 
sometime in the 6-12 day range, and that after that time FURD prevalence decreases with 
the majority of disease occurring within the first 50 days (Edwards et al., 2008). This 
study also agrees with this previous work.  
FHV was detected in a large number of the cats in this study and was not found to 
be significantly related to FURD. This suggests that FHV and M.felis are endemic in the 
environment and animals are constantly exposed to these. The lack of association with 
disease in this study can be attributed to the long term exposure of the cats, early 
infection and maturity of the immune response, and neonatal immunity. It is important 
that both pathogens were detected at high levels suggesting that they are frequently shed 
125 
 
 
 
 
in the saliva and lacrimal fluids and contribute to the environmental pathogen load that 
naïve cats are exposed to on intake. 
This study demonstrates that both Bordetella species and FCV are important 
pathogens in the development of FURD clinical signs in the studied shelter populations.  
Additionally, it appears that C. felis may not be a pathogen detected in cats with FURD 
very often and may not be contributing to FURD disease as commonly as other upper 
respiratory pathogens. Knowledge of the microbial make-up of the shelter population and 
of disease cats allows for triage of the population, and isolation and treatment of affected 
cats in a manner that is both effective and efficient. This study suggests that when 
triaging FURD in upper Midwestern shelters the main pathogens of concern should be 
Bordetella species and FCV. Additional research into the specific Bordetella species 
involved in FURD and infecting cats as well as effective measures to prevent the spread 
of these pathogens both within cat populations and to and from canine populations is 
necessary. 
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GENERAL CONCLUSIONS 
 
This research project was compilation of three studies to investigate FURD in 
Midwestern feline shelter populations and determine what pathogens and risk factors are 
present as well as validate a field deployable device capable of detecting pathogens for 
triage, biosecurity, and population management.  
Results indicated that while the pathogens previously associated with FURD were 
present in these shelter populations (FHV, FCV, C. felis, M. felis, and Bordetella 
species), there are several other Mycoplasma species that can be detected in cats and may 
have involvement in the development and progression of FURD. The first study 
demonstrated detection of 12 Mycoplasma species previously unreported in cats. Of these 
2 are known zoonotic species with transmission to and disease causation reported disease 
in humans. Overall, 15 Mycoplasma species were detected in cats in this study and 7 are 
known to be zoonotic species causing disease in humans. These discoveries greatly 
increase the knowledge about Mycoplasma host-specificity and suggest that cats can be 
carriers and potentially clinically affected by Mycoplasma species that were previously 
assumed to be host-specific pathogens. While detections of atypical Mycoplasma species 
were rare and could not be statistically correlated with disease, the presence of these 
pathogens in cats with severe FURD suggests that further investigation is warranted.  
Validation of the field deployable point of need POCKIT™ device and Insulated 
Isothermal Polymerase Chain Reaction (iiPCR) for the common FURD pathogens 
illustrates a 5 stage pipeline for validation of these devices for field use and triage. The 
iiPCR was found to be sensitive, specific, and exclusive for the FURD pathogens in both 
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pure culture and in clinical samples and future evaluation of this technology will involve 
a field trial and development of standard operating procedures. The ability to have a fast, 
efficient, and cost-effective device and assays that can be implemented in a shelter 
environment for rapid pathogen detection allows for the triage, medical management, and 
population biosecurity necessary to prevent morbidity and mortality in shelter cats. 
Implementation of this technology in conjunction with vaccination, isolation, and other 
preventative medicine and biosecurity protocols can improve the general health of a 
shelters feline population which in turn increases the likelihood of adoptions and a 
healthy feline pet population.  
The epidemiological study of this Midwestern feline population through a cross 
sectional study design allowed for the evaluation of pathogen prevalence in both 
clinically normal cats and those with FURD. Additionally, the factors time in the shelter, 
age, and sex were evaluated. This study evaluated a unique geographically location, 
incorporation of a high number of clinically normal cats, an utilized standardized 
molecular diagnostic testing to evaluate for pathogen presence. Overall, it was found that 
Midwestern shelter populations are very similar to those previously studied in that age 
and time in the shelter affect the feline health outcome. It was also found that the 
presence of the pathogens FCV and Bordetella species significantly increased the odds of 
disease for cats. Bordetella species are emerging infectious diseases in cats with an 
increasing number of studies recognizing their significant role in FURD in shelter 
populations. While work is still needed to differentiate the specific Bordetella species 
affecting these cats and determine if they have an identical genetic signature to 
Bordetella species infecting dogs, humans, and other domestic animal species, it is 
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important to recognize that control of Bordetella  species is essential to management of 
FURD in felines.  
Overall, the findings of these studies contribute to the body of knowledge 
regarding FURD in shelter housed cats and provide indications of areas where 
management and preventative medicine can implement disease preventing measures. 
Additionally, the future validation of a field deployable device and its translation into a 
shelter environment provides a tool for detection and triage of respiratory pathogens. All 
of these findings have direct translational abilities to improve the health of feline shelter 
populations. 
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APPENDIX A. LETTER OF INVITATION FOR SHELTER PARTICIPANTS 
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APPENDIX B. CLIENT CONSENT FOR IN HOSPITAL SAMPLING OF 
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